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Abstract 
In many Western countries, the average cigarette consumption among smokers has decreased, 
with occasional smoking and daily light smoking (<1-4 cigarettes per day, CPD) becoming 
more common. Despite this decrease in smoking frequency, the prevalence of chronic 
obstructive pulmonary disease (COPD), a disorder characterized by progressive decline in 
lung function, continues to rise globally. The risk for COPD increases with smoking 
exposure; however, not all smokers develop COPD. Genetic factors partly explain the 
differences in lung function between individuals, and the susceptibility of some smokers to 
COPD. The proportion of genetic effects influencing lung function varies across time and 
populations. No earlier research on the genetic and environmental determinants of lung 
function or on the phenomenon of light smoking exists in the Finnish population. Further, the 
association between low-rate smoking patterns and COPD remains partly unknown. This 
thesis aimed to study the prevalence and consistency of light smoking longitudinally in the 
Finnish population, to assess the characteristics of light smokers, and to examine the risks of 
chronic bronchitis and COPD associated with changing smoking patterns over time. A further 
aim was to estimate longitudinally the proportions of genetic and environmental factors that 
explain the inter-individual variances in lung function. 
Data from the Older Finnish Twin Cohort, including same-sex twin pairs born in 
Finland before 1958, were used in this study. Three surveys were conducted in 1975, 1981, 
and 1990, including accurate and consistent definitions of smoking and chronic bronchitis 
symptoms. Data used in Studies I, II, and IV were mainly derived from the 1975 and 1981 
surveys. A subsample of the cohort, female twins born in 1924-1937 who attended spirometry 
in 2000 and 2003, formed the sample of Study III. The genetic and environmental influences 
on lung function were estimated by using genetic modeling on the repeated spirometry 
measures. In Study IV, a record-linkage study was performed by combining the twin cohort 
data with that obtained from the Finland's Social Insurance Institution (SII). The SII's data on 
reimbursement eligibilities and medication purchases were used to define COPD. 
This thesis reveals that light smoking is associated with female sex, a healthier 
lifestyle, and a better education. Between 1975 and 1990, the proportion of light smokers in 
Finnish adult smokers remained constant at 8%. However, on an individual level, this pattern 
was rarely constant. Light smoking, reducing from heavier smoking to light smoking, or 
relapsing to light smoking after quitting are among patterns associated with an increased risk 
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of chronic bronchitis and COPD. Constant light smoking is associated with an increased use 
of inhaled anticholinergics, a medication for COPD. In addition to smoking, other 
environmental factors substantially influence lung function in the elderly. During a three-year 
follow-up, new environmental effects influencing spirometry values emerged, whereas the 
genes affecting lung function remained mostly the same. 
In conclusion, no safe level of daily smoking exists with regard to pulmonary diseases. 
Even daily light smoking in middle-age is associated with increased respiratory morbidity. 
Light smoking is rarely a constant pattern, and light smokers need cessation interventions in 
order to prevent them from progressing towards heavier smoking. Smoking reduction does 
not decrease the risk of COPD and should not be recommended as an alternative to quitting 
smoking. In elderly people, attention should also be drawn to other factors that can prevent 
poor lung function. 
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Tiivistelmä 
Useissa länsimaissa tupakoitsijoiden päivittäinen savukkeiden määrä on pienentynyt ja 
satunnaistupakointi sekä määrältään vähäinen päivittäistupakointi (1-4 savuketta päivässä) 
ovat yleistyneet. Tupakointimäärien vähenemisestä huolimatta keuhkoahtaumataudin 
esiintyvyys maailmassa jatkaa kasvuaan. Keuhkoahtaumatauti on etenevä sairaus, jossa 
keuhkojen toiminta on pysyvästi heikentynyt. Vaikka altistus tupakansavulle onkin tärkein 
keuhkoahtaumataudin riskitekijä, kaikki tupakoitsijat eivät sairastu. Geneettiset tekijät 
vaikuttavat sairastumisalttiuteen ja selittävät osan yksilöiden välisistä eroista keuhkojen 
toimintakapasiteetissa. Geneettisten tekijöiden selitysosuus keuhkotoiminnan yksilöiden 
välisestä vaihtelusta riippuu tutkimusajankohdasta ja –väestöstä. Suomalaisessa väestössä ei 
ole aiemmin tutkittu määrältään vähäistä tupakointia eikä geneettisten tekijöiden ja 
ympäristötekijöiden vaikutusta keuhkotoimintaan. Erilaisten vähäisten tupakointitapojen ja 
niissä tapahtuvien muutosten yhteys krooniseen bronkiittiin ja keuhkoahtaumatautiin 
tunnetaan myös puutteellisesti. Tämän väitöskirjan tavoitteena oli tutkia pitkittäisasetelmalla 
suomalaisessa väestössä määrältään vähäisen tupakoinnin esiintyvyyttä ja pysyvyyttä, 1-4 
savuketta päivässä tupakoivien ominaispiirteitä, sekä erilaisten vaihtelevien ja muuttuvien 
tupakointitapojen yhteyttä krooniseen bronkiittiin ja keuhkoahtaumatautiin. Lisäksi 
tavoitteena oli arvioida geneettisten tekijöiden ja ympäristötekijöiden selitysosuuksia 
yksilöiden välisestä keuhkotoiminnan vaihtelusta. 
Aineistona käytettiin Suomen kaksoskohorttitutkimuksen kolmea kyselyaineistoa 
vuosilta 1975, 1981 ja 1990. Kohorttiin oli poimittu väestörekisteristä Suomessa ennen vuotta 
1958 syntyneet kaksoset. Kyselyissä on tutkittu tupakointitavat sekä kroonisen bronkiitin 
oireet yksityiskohtaisesti ja yhtenevällä tavalla. Ensimmäisen, toisen ja neljännen osatyön 
aineiston muodostivat lähinnä vuosien 1975 ja 1981 kyselyihin vastanneet henkilöt. 
Kolmannen osatyön aineistona käytettiin kaksoskohortin alaotosta, vuosina 1924-37 
syntyneitä naiskaksospareja, jotka osallistuivat spirometriamittauksiin vuosina 2000 ja 2003. 
Geneettisten tekijöiden ja ympäristötekijöiden selitysosuudet spirometriatulosten yksilöiden 
välisestä vaihtelusta arvioitiin käyttämällä geneettistä mallinnusta. Neljännessä osatyössä 
kaksoskohorttiaineistoon yhdistettiin Kansaneläkelaitoksen rekisteriaineistoa, josta saatua 
tietoa lääkeostoista sekä lääkkeiden erityiskorvattavuuksista käytettiin keuhkoahtaumataudin 
määrittelemiseksi. 
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Tutkimuksessa havaittiin, että määrältään vähäinen tupakointi oli yksilötasolla harvoin 
pysyvä tapa, vaikka tupakoitsijoiden joukossa 1-4 savuketta päivässä tupakoivien osuus oli 
8% kaikissa mittauspisteissä. Kun 1-4 savuketta päivässä tupakoivia verrattiin yli 20 
savuketta päivässä tupakoiviin, oli vähäinen tupakointi todennäköisempää naisilla, terveellisiä 
elintapoja noudattavilla ja hyvin koulutetuilla ihmisillä. Runsaampien tupakointimäärien 
lisäksi vähäinen päivittäistupakointi, siihen vähentäminen runsaamman tupakoinnin jälkeen 
tai tupakoinnin uudelleen aloittaminen lopettamisen jälkeen olivat yhteydessä 
suurentuneeseen kroonisen bronkiitin ja keuhkoahtaumataudin riskiin. Pysyvä 1-4 savukkeen 
päivittäistupakointi oli yhteydessä lisääntyneeseen inhaloitavien antikolinergien käyttöön, 
joka on eräs keuhkoahtaumataudin lääkehoidoista. Tupakoinnin lisäksi myös muut 
ympäristötekijät vaikuttavat huomattavasti keuhkotoimintaan vanhemmalla iällä. Kolmen 
vuoden seurannan aikana havaittiin, että spirometria-arvoihin vaikuttavat geneettiset tekijät 
pysyivät valtaosin samoina, kun taas ympäristötekijöistä valtaosa oli kullekin 
seurantapisteelle ominaisia. 
Tutkimustulokset tukevat käsitystä siitä, että vähäinenkin tupakointi voi vahingoittaa 
keuhkoja. Vähäinen päivittäistupakointi keski-iässä lisää myöhemmin kehittyvien 
hengitysteiden sairauksien riskiä. Määrältään vähäinen tupakointi on harvoin pysyvä tapa. 
Jotta 1-4 savuketta päivässä tupakoivat eivät siirtyisi runsaampaan tupakointiin, he tarvitsevat 
tukea tupakoinnin lopettamiseen. Tupakoinnin vähentämistä ei voi suositella vaihtoehtona 
lopettamiselle, sillä tupakoinnin vähentäminen ei pienennä keuhkoahtaumataudin 
kehittymisen riskiä. Jotta voitaisiin ehkäistä ikääntyvien ihmisten keuhkotoiminnan 
ennenaikaista alenemista, tulee kiinnittää huomiota myös muihin riskitekijöihin kuin 
tupakointiin.  
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1. Introduction 
Smoking is the most important preventable cause of premature morbidity and mortality 
(Ezzati et al. 2002). Among leading causes of deaths from smoking are cardiovascular 
diseases, chronic obstructive pulmonary disease (COPD), and lung cancer (Ezzati & Lopez 
2003). The total number of tobacco-attributable deaths, 5.4 million in 2005, has been 
estimated to reach 8.3 million by 2030 and to account for 10% of all deaths globally. COPD-
related mortality is increasing sharply, particularly in developing countries, where the number 
of all smoking-induced deaths has been projected to double by 2030. In high-income 
countries, COPD is the major chronic disease for which death rates are increasing (World 
Health Organization 2004, Mathers & Loncar 2006, Global Alliance against Chronic 
Respiratory Diseases 2007). 
Awareness of the deleterious health effects of smoking started to spread in the 1950s. 
Large epidemiological studies were designed when the increase in lung cancer rates was 
observed, and soon results on the associations between smoking and cardiovascular diseases, 
chronic bronchitis, and emphysema were also published (U.S. Surgeon General's Advisory 
Committee on Smoking and Health 1964, Peto 1994). Chronic bronchitis and emphysema had 
been considered as different entities for decades, but were recognized to be clinical 
manifestations of the same disease in the 1960s. The common term chronic obstructive 
pulmonary disease was first introduced in 1965 (Fishman 2005, Petty 2006). In 1977, Fletcher 
described the association between smoking and accelerated lung function decline (Fletcher & 
Peto 1977).  
In Finland, the prevalence of smoking among men was almost 70% in the 1950s, 
decreasing to 45% by 1965-1970. In contrast, only about 13% of women smoked at the 
beginning of the 1960s, whereas the proportion had increased to 17% by 1978 (Helakorpi et 
al. 2004). The Tobacco Act, passed in 1976, restricted tobacco advertising and smoking in 
public places, and set the age limit of tobacco purchases to 16 years (Helakorpi et al. 2008a). 
Since then, the prevalence of smoking in men has steadily decreased. In women, by contrast, 
smoking rates have been declining only since the 1990s. In the 21st century, amendments have 
been made to the Tobacco Act, and the trend of decreasing smoking rates continues: the 
proportion of former smokers has increased, and smokers' daily number of cigarettes has 
decreased (Helakorpi et al. 1999, Helakorpi, Laitalainen & Uutela 2010). However, light 
smoking (1-4 cigarettes per day), an increasingly common pattern globally (Okuyemi et al. 
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2002, Zhu et al. 2003, Pierce, White & Messer 2009), has not been studied in the Finnish 
population. 
Fletcher noted that some smokers had a steeper decline in lung function than others, 
and termed them 'susceptible smokers' (Fletcher & Peto 1977). Genetic factors have been 
stated to account for the observed differences between subjects in susceptibility to cigarette 
smoke and COPD development (Mannino & Buist 2007, Sorheim et al. 2010). Heritability 
refers to the proportion of inter-individual variance explained by genetic factors. Reported 
heritability estimates for lung function have been inconsistent, varying across populations. 
Smoking is one factor complicating these heritability studies, as it modifies the expression of 
genes influencing lung function (Silverman et al. 1998, Wilk et al. 2000). 
In many populations, different low-rate smoking patterns are increasing (Okuyemi et 
al. 2002, Zhu et al. 2003, Pierce, White & Messer 2009). Previous smoking research has 
focused mainly on heavier smoking patterns, and the health effects of low-rate smoking 
remain partly unknown. Research evidence has shown that light smoking also causes 
cardiovascular diseases and lung cancer as well as increased mortality (Bjartveit & Tverdal 
2005, Schane, Ling & Glantz 2010). Light and passive smoking seem to be associated also 
with respiratory symptoms (Radon et al. 2002, Amigo et al. 2006); however, whether light 
smokers are at risk for COPD remains to be elucidated. Moreover, longitudinal studies on the 
respiratory consequences of reduced smoking are few, although the average daily amount of 
cigarettes among smokers has diminished considerably. 
The Older Finnish Twin Cohort includes comprehensive data on smoking patterns and 
respiratory symptoms of over 30,000 Finnish twins over a 15-year period. Spirometry has 
been performed for a subgroup of this cohort. The cohort offers a unique opportunity to study 
the changes that take place in smoking over time, reflecting the smoking patterns in the 
population. Moreover, by combining Finland's Social Insurance Institution’s high-coverage 
medication data with the twin cohort data, the development of respiratory diseases can be 
traced even decades after the end of the cohort. This thesis focused on investigating the 
subgroup of light smokers, the heritability of lung function, and the associations of different 
smoking patterns with chronic bronchitis and COPD by taking full advantage of these 
extensive databases.
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2. Review of the literature 
2.1. Definitions of different smoking patterns 
Traditionally, researchers have grouped smokers into occasional (intermittent, nondaily), 
current daily, and former smokers. A person reporting having consumed at least 100 
cigarettes during his/her lifetime is usually considered an ever smoker, although other 
definitions are also sometimes used (Giovino 2002, Helakorpi, Laitalainen & Uutela 2010). 
Based on the frequency of cigarette consumption, current smokers are divided into daily and 
occasional smokers. Those ever smokers who have not smoked for a certain time period, often 
for 6 or 12 months, are considered former smokers (Hughes et al. 2003). In epidemiological 
studies, however, it is common to classify all ever smokers who state that they no longer 
smoke as former smokers (Giovino 2002).  
 Daily smokers have usually been subdivided into those consuming <15, 15-24, and 
over 25 cigarettes per day (CPD) (Okuyemi et al. 2002, Helakorpi, Prättälä & Uurtela 2008), 
those with greater consumption being the main focus of smoking studies (Shiffman 2009). In 
the 1990s, researchers became interested also in daily smokers consuming <5 and <10 CPD 
(Shiffman 1989, Rosengren, Wilhelmsen & Wedel 1992, Shiffman et al. 1994, Hajek, West & 
Wilson 1995, Owen et al. 1995). Such smokers have been called, for example, ‘chippers’ 
(Kassel et al. 1994, Shiffman et al. 1994), ‘low-rate smokers’ (Owen et al. 1995, Zhu et al. 
2003), ‘low-level smokers’ (Hyland et al. 2005), ‘light smokers’ (Rosengren, Wilhelmsen & 
Wedel 1992, Bjartveit & Tverdal 2005), and ‘very light smokers’ (Levy, Biener & Rigotti 
2009). The term ‘light smoking’ has been used to describe smokers consuming up to 20 CPD, 
although usually 10 CPD (Husten 2009, Levy, Biener & Rigotti 2009) or 5 CPD (Rosengren, 
Wilhelmsen & Wedel 1992, Bjartveit & Tverdal 2005) are used as cut-off levels. Light and 
intermittent smokers are sometimes also grouped together in a category called ‘LITS’ (Pierce, 
White & Messer 2009, Shiffman 2009).  
2.2. Low-rate smoking patterns 
2.2.1. Prevalence of low-rate smoking patterns 
While the prevalence of smoking is decreasing in Western countries, the proportions of light 
and occasional smokers are on the rise (Okuyemi et al. 2002, Zhu et al. 2003, Giskes et al. 
2005, Pierce, White & Messer 2009). Smoking cessation rates have increased, and daily 
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smokers’ average number of cigarettes has decreased in recent decades (Pierce, White & 
Messer 2009, Helakorpi, Laitalainen & Uutela 2010, Marques-Vidal et al. 2011). The 
observed trend is most evident among well-educated subjects (Giskes et al. 2005). In Finland, 
the proportion of smokers consuming 1-14 CPD increased between 1999 and 2009, while 
consumption of more CPD became less prevalent. Similarly, the proportion of daily smokers 
decreased from 23.3% to 18.6%, and the proportion of quitters increased from 17.1% to 
20.3% (Helakorpi et al. 1999, Helakorpi, Laitalainen & Uutela 2010). In Finland, the 
prevalence of occasional smoking in the population between 1978 and 2009 has remained 
constant at 6-6.5% (Helakorpi et al. 1999, Luoto, Uutela & Puska 2000, Helakorpi, 
Laitalainen & Uutela 2010). Thus, as daily smoking has become less prevalent, the relative 
proportion of occasional smokers has increased. Occasional smoking is particularly common 
among young adults and women (Luoto, Uutela & Puska 2000, Korhonen et al. 2009). 
 International studies in the 1990s reported that the proportion of smokers consuming 
<5 CPD is 4-8% among daily smokers (Rosengren, Wilhelmsen & Wedel 1992, Owen et al. 
1995, Zhu et al. 2003). In the US, the proportion of light and occasional smokers among all 
smokers has recently been estimated to be 20-30% (Shiffman 2009), and the increase has 
been greatest among young adults (Pierce, White & Messer 2009). Light smoking is 
particularly common among women, adolescents, and well-educated persons (Owen et al. 
1995, Okuyemi et al. 2002, Hyland et al. 2005, Levy, Biener & Rigotti 2009, Pierce, White & 
Messer 2009). No studies on light smokers in the Finnish population have been published. 
 Light smokers form a heterogeneous subgroup of daily smokers, where some are well 
established in this pattern, while others are progressing towards heavier use or towards 
cessation (Owen et al. 1995, Okuyemi et al. 2002, Zhu et al. 2003, Hyland et al. 2005, Levy, 
Biener & Rigotti 2009). Longitudinal studies report that light smokers are rarely consistent in 
their smoking habit (Zhu et al. 2003, Etter 2004, Levy, Biener & Rigotti 2009), although 
some individuals can maintain this pattern for long periods of time (Owen et al. 1995, Hyland 
et al. 2005). 
2.2.2. Factors contributing to low-rate smoking 
Light smokers have been suggested to be more motivated by social and enjoyment factors 
than by nicotine addiction (Shiffman et al. 1994). Some studies have found that light smokers 
do not suffer from withdrawal symptoms while abstinent (Shiffman 1989, Okuyemi et al. 
2002). Indeed, it has been suggested that by smoking 1-4 CPD a steady-state nicotine level 
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cannot be maintained (Shiffman et al. 1990). However, many smokers accustomed to heavier 
smoking rates are able to reduce their smoking for substantial periods of time (Hughes 2000). 
 Smoking restrictions at home and at the workplace as well as society’s tobacco 
prohibitions and high taxation of tobacco products are associated with reduced smoking 
(Okuyemi et al. 2002, Jha et al. 2006, Pierce, White & Messer 2009). Also in Finland, 
changes in tobacco policy have contributed to the decline in daily smoking (Helakorpi et al. 
2004, Helakorpi 2008). The Tobacco Act was passed in 1976, and amendments in 1995 and 
2007 raised the age limit of purchasing tobacco products and prohibited smoking in many 
public places (Helakorpi et al. 2004, Helakorpi et al. 2008b). Further amendments in 2010 
aim at ending the use of tobacco products in Finland. Prevalence of smoking in men has been 
decreasing since the 1970s, whereas smoking rates in women increased slightly until the mid-
1980s, remained at a constant level for a while, and have been declining since the 1990s 
(Helakorpi, Laitalainen & Uutela 2010). Attitudes towards smoking cessation restrictions are 
positive in Finland (Nieminen et al. 2010). 
 Some smokers, e.g. pregnant women, are worried about the health effects of smoking 
and aim at ‘harm reduction’ by smoking fewer cigarettes (Okuyemi et al. 2002). Light 
smokers have been reported to be less impulsive and more self-disciplined than heavier 
smokers (Shiffman 1989, Kassel et al. 1994). Compared with heavier smokers, light smokers 
attempt quitting more often (Owen et al. 1995, Zhu et al. 2003, Hyland et al. 2005) and are 
better educated (Hajek, West & Wilson 1995, Pierce, White & Messer 2009). Finnish studies 
have found that occasional smokers are better educated, physically more active, and have a 
healthier diet than regular smokers (Luoto, Uutela & Puska 2000, Korhonen et al. 2009), 
suggesting that health-related issues might restrict their smoking patterns. Whether Finnish 
light smokers exhibit similar characteristics is thus far unknown. 
 Use of snus, a moist oral tobacco powder, is common in Sweden, whereas only 3% of 
the population in neighboring Finland report using it (Patja et al. 2009). In Sweden and 
Norway, substantial proportions of snus users concomitantly smoke cigarettes (Patja et al. 
2009, Lund et al. 2011). This type of dual use may help smokers to adapt to small amounts of 
daily cigarettes. However, such behavior was unlikely to occur in Finland in the 1970s-1980s, 
when the use of snus was even more rare than today (IARC Working Group on the Evaluation 
of Carcinogenic Risks to Humans 2007). 
 Genetics influence the age of smoking initiation, the daily amount smoked, and 
nicotine dependence (Broms et al. 2006, Ho & Tyndale 2007, Thorgeirsson et al. 2010). 
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Reported heritability estimates for nicotine dependence and smoking behavior have been 
consistently high, albeit varying (Broms et al. 2006, Ho & Tyndale 2007, Korhonen et al. 
2009). Multiple genome-wide association studies (GWAs) have demonstrated that the 
nicotinic acetylcholine receptor (nAChR) gene complex on chromosome 15 is associated with 
smoking behavior and nicotine dependence, as well with lung cancer and COPD (Saccone et 
al. 2010, Siedlinski et al. 2011). However, genetic variants at this locus explain only 1% of 
the observed variance in the amount smoked (Thorgeirsson et al. 2008). Another example of 
the genetic variance affecting smoking behavior is the nicotine-metabolizing enzyme 
CYP2A6 (Thorgeirsson et al. 2010, Siedlinski et al. 2011). Individuals with a slow variant of 
CYP2A6 experience less craving and withdrawal symptoms because of the slower 
inactivation of nicotine (Okuyemi et al. 2002, Ho & Tyndale 2007). This variant may be one 
reason why some smokers can maintain low consumption levels. However, smoking reducers 
sometimes compensate for nicotine reduction by inhaling more deeply (Scherer 1999). 
Genomic regions encoding for example other nicotinic receptors and CYP2B6 have also been 
reported to be associated with smoking behavior (Thorgeirsson et al. 2010), and smoking has 
been shown to modify genetic expression of multiple traits (Zeller et al. 2010). Nicotine 
dependence and smoking are, however, complex disorders, where the phenotype is likely to 
be a result of an interaction between environmental factors and multiple genetic factors (Ho & 
Tyndale 2007). Accordingly, genetics cannot totally explain the phenomenon of light 
smoking, particularly its increasing prevalence. 
2.2.3. Health effects 
Light smoking has been demonstrated to be associated with an almost similar risk for 
cardiovascular diseases as heavier smoking patterns (Schane, Ling & Glantz 2010). Light 
smoking increases cardiovascular and overall mortality (Luoto, Uutela & Puska 2000, 
Bjartveit & Tverdal 2005), as well as the risk for lung and gastrointestinal cancers 
(Rosengren, Wilhelmsen & Wedel 1992, Schane, Ling & Glantz 2010). Smoking 1-4 CPD 
has also been shown to impair reproductive health (Schane, Ling & Glantz 2010). 
 No consensus exists about whether smokers can diminish their health risks by 
reducing the number of daily cigarettes (Hughes & Carpenter 2006). Cohort studies report 
that smoking reduction has no effect on mortality (Godtfredsen et al. 2002, Tverdal & 
Bjartveit 2006), hospital admissions due to COPD (Godtfredsen et al. 2002), or risk of 
myocardial infarction (Godtfredsen et al. 2003). However, large reductions in smoking have 
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been reported to reduce lung cancer risk (Godtfredsen, Prescott & Osler 2005) and the decline 
rate of FEV1 (Simmons et al. 2005), at least before the age of 55 years (Lange et al. 1989). 
Other results, by contrast, suggest that reduction improves respiratory symptoms, but has no 
effect on FEV1 decline (Bohadana et al. 2006, Pisinger & Godtfredsen 2007). A Finnish 
cohort study found that smokers with chronic bronchitis can improve their life expectancy by 
reducing their smoking (Pelkonen et al. 2006). 
 The extent to which light smoking affects the lungs is unclear. Cross-sectionally 
measured, light smoking has been reported to be associated with wheezing, shortness of 
breath, and cough, but not with chronic bronchitis (Pallasaho et al. 2002, Amigo et al. 2006). 
Some evidence has emerged that long-term passive smoking can cause chronic bronchitis 
(Radon et al. 2002, U.S. Department of Health and Human Services 2006, Mannino & Buist 
2007), but whether light smoking can permanently reduce pulmonary function or cause 
COPD remains unknown. 
 Although light smokers are subjected to numerous health risks, studies have shown 
that they are rarely advised to quit smoking (Owen et al. 1995, Okuyemi et al. 2001). 
However, cessation interventions are important also for light smokers: after quitting, for 
example, smokers having consumed on average 7 CPD demonstrate similar relapse rates as 
heavy smokers (Choi et al. 2004). Studies on smoking cessation pharmacotherapies are 
mostly restricted to smokers consuming >10 CPD. Nicotine replacement therapy, bupropion, 
or varenicline are not recommended for light smokers, instead, behavioral therapies should be 
offered to them as well (Robinson, Schroeder & Moolchan 2006, Tønnesen et al. 2007, 
Cahill, Stead & Lancaster 2011). 
2.3. Lung function 
2.3.1. Measuring lung function 
Spirometry is the most common and practical way to appropriately measure ventilatory 
function. It has been defined as “a physiological test that measures how an individual inhales 
or exhales volumes of air as a function of time” (Miller et al. 2005b). Subjects perform 
maximal and forced exhalations into a spirometer attached to a computer, which creates flow-
volume and volume-time curves. Good cooperation and repeated measures are necessary to 
achieve reliable results (Miller et al. 2005b). If the testee suffers from, for example, chest 
pains or dementia, or has smoked, used alcohol, or bronchodilators prior to spirometry, the 
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results are easily suboptimal. The most important and informative values in spirometry are 
forced expiratory volume in one second (FEV1), slow vital capacity (VC) or forced vital 
capacity (FVC), and total lung capacity (TLC) (Viljanen 1982, Miller et al. 2005a). 
 In restrictive disorders, the ratio of FEV1/VC or FEV1/FVC is normal, while TLC is 
reduced (Pellegrino et al. 2005, Mannino et al. 2006). Instead, a reduced ratio of FEV1/VC or 
FEV1/FVC and a reduced FEV1 are characteristic of obstructive ventilatory disorders. To test 
the reversibility of airflow limitation, bronchodilators are administered to the testee, and lung 
function values are measured again after medication. Low values of FEV1/FVC and FEV1 
even after inhalation of bronchodilators are typical of COPD, whereas in asthma the decrease 
is reversible (GOLD 2010).  
 Interpretation of spirometry measures is based on comparisons made between the 
testee and reference values derived from a healthy general population. Reference equations 
are calculated by taking into account subjects’ sex, age, and height. Ideally, the reference 
values are derived from a population ethnically similar to the individual tested (Pellegrino et 
al. 2005). Reference equations vary according to race, and those used in the US and in Europe 
are different (Quanjer et al. 1993, Hankinson, Odencrantz & Fedan 1999). In Finland, use of 
national age- and height-adjusted reference values is recommended (Viljanen 1982, Sovijärvi 
et al. 2006).  
2.3.2. Natural history of lung function 
The natural history of lung function and the drastic effect of smoking on it were first explored 
in the 1970s in a sample of working men (Fletcher & Peto 1977). Studies with longer follow-
up times and larger samples have increased the current knowledge of lung function decline 
and influencing factors (Xu et al. 1994, Mannino & Davis 2006, Kohansal et al. 2009).  
 FEV1 and FVC grow linearly until the age of 10-12 years, while during adolescence 
their increase is more complex (Wang et al. 1993). In males, lung function peaks around the 
age of 23 and in females this happens earlier and the plateau phase is longer (Kohansal et al. 
2009). Men have greater absolute lung function measures than women, even when adjusted 
for height (Pellegrino et al. 2005). Many environmental factors during lung development, 
such as maternal smoking during pregnancy, passive and active smoking, asthma and airway 
hyperresponsiveness, and respiratory tract infections during childhood, may impair the 
achievement of maximal lung function (Bakke 2003) or result in a shortened plateau phase 
(Kerstjens et al. 1997). Interestingly, low socioeconomic status is associated with poor lung 
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function, even after adjustment for smoking, occupational risk factors, and race (Prescott, 
Lange & Vestbo 1999, Hegewald & Crapo 2007). An association between mental health 
problems and poor lung function has been observed in both adults (Goodwin et al. 2007) and 
children (Whitrow & Harding 2008); the underlying mechanism remains unclear. 
 After having reached maximum values, lung function begins to decrease. The decline 
rate of FEV1 varies between 20 and 40 ml/year (Kerstjens et al. 1997, Wise 2006, Kohansal 
et al. 2009), greater rates being observed in men (Kerstjens et al. 1997, Wise 2006). The 
above-mentioned environmental risk factors, particularly smoking, may speed up the age-
related decline in lung function (Amara et al. 2001, Stern et al. 2007). Marked individual 
variation exists in the rate of lung function decline due to environmental exposure. Physically 
active individuals can maintain better lung function longer (Amara et al. 2001), whereas 
weight gain is associated with an enhanced decline in lung function (Chen, Horne & Dosman 
1993, Wang et al. 1996, Thyagarajan et al. 2008). The effect of obesity is more pronounced in 
men than in women (Chen, Horne & Dosman 1993, Steele et al. 2009). Finally, lung function 
decline accelerates after the age of 65 years (Mannino & Davis 2006, Wise 2006). Even in 
healthy elderly individuals, multiple physiological modifications occur in the lungs with age, 
including loss of elastic recoil, decrease in oxygen diffusion capacity, and premature airway 
closure. These changes are similar to those observed in emphysema, and together with 
sarcopenia and anatomical changes of the chest wall, they result in smaller lung function 
values (Chan & Welsh 1998). 
2.3.3. Lung function and smoking 
Smoking is the most important factor enhancing the age-related decline in FEV1 (Kerstjens et 
al. 1997, Viegi et al. 2007). The risk of a significant obstruction increases with lifetime 
cumulative exposure to tobacco, independent of current smoking status (Burrows et al. 1977, 
Rennard & Vestbo 2006). Smoking cessation can normalize the accelerated decline in FEV1 
(Anthonisen, Connett & Murray 2002, Bohadana et al. 2006, Kohansal et al. 2009), but 
smokers apparently should quit before middle age in order to attain this beneficial effect 
(Murray et al. 1998, Kohansal et al. 2009). Some studies report that reduction in daily 
cigarettes may slow down the decline in FEV1 (Lange et al. 1989, Simmons et al. 2005); 
others state that reduction has no effect on FEV1 (Bohadana et al. 2006, Pisinger & 
Godtfredsen 2007). Those who try to quit smoking, but relapse and become “intermittent 
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quitters”, have slower loss of lung function than those who continue daily smoking 
(Anthonisen, Connett & Murray 2002).  
 Individual responses to tobacco smoke are different, and not all smokers eventually 
develop COPD. Multiple studies suggest that symptomatic smokers, i.e. those suffering from, 
for instance, chronic bronchitis, wheezing, or dyspnea, are more susceptible and have a 
steeper decline in FEV1 than asymptomatic smokers (Sherrill et al. 1991, Sherman et al. 
1992, Tishler et al. 2002, de Marco et al. 2007, Kohansal et al. 2009). Women seem to be 
more susceptible to the effects of cigarette smoke and develop COPD more easily than men 
(Prescott et al. 1997, Langhammer et al. 2003, Foreman et al. 2011). 
2.3.4. Heritability of lung function 
Phenotypic differences between individuals are due to both environmental and genetic factors. 
Heritability is defined as the proportion of inter-individual variance explained by genetic 
factors. Because genetic and environmental effects vary across time and populations, 
heritability estimates are not constant. Genetic variance in a population can be divided into 
additive (A), dominant (D), and epistatic genetic effects. If the common effect of gene alleles 
at a locus is the sum of their individual effects, the effect is additive. Dominant effects are 
those deviating from purely additive effects, and epistatic effects refer to the interaction 
between alleles at different loci. Environmental factors can also modify genetic effects (GxE 
interaction). Heritabilities of different phenotypes can be estimated by comparing the 
similarities between monozygotic (MZ) and dizygotic (DZ) twins. The classic twin design is 
based on the assumption that MZ twins share all, while DZ twins share on average 50%, of 
their segregating genes (Evans, Gillespie & Martin 2002). 
 COPD sometimes clusters in families, and susceptibility to tobacco smoke differs 
between individuals (Sandford, Weir & Pare 1997, Wan & Silverman 2009). These 
observations have suggested that genetic effects control lung function. To estimate its 
heritability, twin and family studies have analyzed spirometry values. Lung function has been 
shown to be influenced by both genetic and environmental factors; however, the reported 
effects of aging, sex, and smoking on heritability are controversial. Multivariate-adjusted 
heritability estimates are 10-67% for FEV1, 40-59% for FVC, and 45% for the FEV1/FVC 
ratio (McClearn et al. 1994, Wilk et al. 2000, Palmer et al. 2001, Hallberg et al. 2010).  
In the 1980s, some twin and family studies found that no significant lung function 
heritability exists after adjustment for body habitus or height (Hubert et al. 1982, Lebowitz, 
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Knudson & Burrows 1984, Ghio et al. 1989), while others reported high heritability estimates 
(Lewitter et al. 1984, Redline et al. 1987). Results obtained in segregation analyses of lung 
function were also controversial; both polygenic genetic factors and environmental factors 
(Chen et al. 1996, Givelber et al. 1998) as well as a major gene effect (Wilk et al. 2000) have 
been suggested to control FEV1. Studies using quantitative genetic modeling have 
consistently reported that the observed variance in spirometry values can be decomposed into 
additive genetic effects and environmental effects (Palmer et al. 2001, Zhai et al. 2007, 
Hallberg et al. 2010). Aging and smoking, however, influence the heritability estimates of 
lung function, and taking into account the effect of smoking has either increased or decreased 
heritability estimates (Coultas et al. 1991, McClearn et al. 1994, Zhai et al. 2007). Results on 
sex differences in lung function are also controversial (McClearn et al. 1994, Hallberg et al. 
2010).  
Limitations of lung function heritability studies include cross-sectional study design 
and inclusion of both smokers and nonsmokers, which makes it difficult to control for the 
smoking-gene interaction. Lung function is likely to be influenced by a substantial GxE 
interaction (Silverman et al. 1998, Wilk et al. 2000, Zhai et al. 2007), and smoking has been 
shown to modify the expression of multiple genes (Zeller et al. 2010). Further, studies have 
assessed pulmonary function at only one time-point, although heritability estimates may 
change over time as a result of aging and changing environmental exposures. Repeated 
spirometry measurements have been used only in one study, which estimated the heritability 
of the lung function decline rate (Gottlieb et al. 2001). 
Candidate gene studies, performed on both subjects with respiratory diseases and 
general populations, have identified over 100 genes suggested to control pulmonary function. 
The reported associations have not, however, been consistent across different studies. A 
recent meta-analysis re-analyzed the reported candidate single-nucleotide polymorphisms 
(SNPs) of lung function in a large population sample. All previously reported associations 
were found to be nonsignificant, and the strongest relations with FEV1 were in the 
phosphodiesterase 4D (PDE4D) gene and the SERPINA1 gene encoding the alpha-1 
antitrypsin protein (AAT) (Obeidat et al. 2011). In the lungs, PDE4 regulates smooth muscle 
contractility, and its expression is associated with chronic inflammation (Soto & Hanania 
2005). A mutation in SERPINA1 leads to AAT deficiency, which has been known for 
decades to be the most important genetic disorder predisposing to COPD (Wan & Silverman 
2009).  
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As shown by heritability studies, pulmonary function is likely to result from an 
interaction between multiple genes and the environment. In recent years, GWAs have become 
a popular means of examining the genetic background of complex diseases. By investigating 
the genomic variants of hundreds of thousands of subjects, GWAs have identified multiple 
SNPs associated with FEV1 and the FEV1/FVC ratio (Wilk et al. 2009, Hancock et al. 2010, 
Repapi et al. 2010). Some of these associations have been consistently replicated, while others 
only in certain populations. The identified SNPs have been located in different chromosomes, 
interestingly one also in chromosome 15, near the nAChR gene (Hancock et al. 2010). 
However, these variants have small effects and explain <1% of the variation in lung function. 
Thus, the genetic pathways influencing lung function mostly remain unidentified. 
2.4. Chronic bronchitis 
2.4.1. Definition and history 
Chronic bronchitis is defined as chronic cough and mucus production from the airways for at 
least three months per year for at least two successive years. Inflammation of the mucosal 
surface, mucous gland hyperplasia, and changes in the cell proportions of the airways are 
characteristic pathological changes in chronic bronchitis (Barnes et al. 2002). The diagnosis is 
clinical and is based on the presence of symptoms, which are often screened with 
standardized questionnaires, such as the British Medical Research Council (MRC) series of 
questions, already published in 1960 (British Medical Research Council 1960). Chronic 
bronchitis is a reversible state (Willemse et al. 2004), but it can also affect patients with 
COPD and permanent airflow limitation. 
 Chronic bronchitis was first defined in the CIBA Guest Symposium in 1959, where the 
term ‘chronic’ was specified as “occurring on most days for at least three months of the year 
for at least two consecutive years” (Fletcher et al. 1959). The common term COPD was 
introduced in 1965 (Petty 2006); however, ‘chronic bronchitis’ and ‘emphysema’ were 
commonly used as diagnoses until the 1970s. Since then, use of the term ‘COPD’ started to 
increase and it largely replaced those terms (GOLD 2010). Today, chronic bronchitis refers to 
long-standing symptoms, and emphysema is a pathological term referring to alveoli 
destruction (GOLD 2010). In Finland, 'chronic bronchitis' and 'emphysema' were occasionally 
used as diagnoses for COPD still in the 1980-1990s. 
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2.4.2. Smoking and other risk factors 
Smoking is the most important risk factor for chronic bronchitis (Sethi & Rochester 2000), 
and the disease has been estimated to affect as many as 40% of smokers (Pelkonen et al. 
2006). Although the prevalence of chronic bronchitis increases with age and pack-years of 
smoking, the disease also affects young adults, even those under 20 years of age (Cerveri et 
al. 2001, de Marco et al. 2007, Hamari et al. 2010). However, many smokers become 
accustomed to their respiratory symptoms and consider themselves healthy (Toljamo et al. 
2010). Recovery from chronic bronchitis may be achieved after smoking cessation (Brown et 
al. 1991, Willemse et al. 2004) but smoking reduction does not appear to have a similar 
beneficial effect (Simmons et al. 2005, Bohadana et al. 2006). No evidence exists whether 
light smoking can cause chronic bronchitis. A Finnish study found the risk of chronic 
bronchitis to be increased only among smokers consuming >5 CPD (Pallasaho et al. 1999). 
However, other studies have reported that even passive and occasional smoking can cause 
chronic bronchitis (Radon et al. 2002, Mannino & Buist 2007, Yin et al. 2007, Hamari et al. 
2010). 
 In addition to smoking, other known risk factors for chronic bronchitis are asthma, 
atopy (Terho, Koskenvuo & Kaprio 1995), history of respiratory tract infections (Lange et al. 
2003), farming, industrial work (Laasonen & Uitti 2001, Eduard, Pearce & Douwes 2009), 
outdoor work (Kotaniemi et al. 2003), exposure to biomass fuels, and occupational exposure 
to gases, dusts, or fumes (Lange et al. 2003, Eduard, Pearce & Douwes 2009, Salvi & Barnes 
2009). Physical activity slows down age-related pulmonary function decline regardless of 
smoking status (Pelkonen et al. 2003, Garcia-Aymerich et al. 2007), and, to some extent, 
seems to protect from chronic bronchitis (Kujala et al. 1996). Genetic factors independent of 
smoking play a role in the susceptibility of developing chronic bronchitis (Svartengren et al. 
2009). 
2.4.3. Epidemiology of chronic bronchitis 
The European Community Respiratory Health Survey (ECRHS) has estimated the prevalence 
of different respiratory diseases in young adults of 35 centers from 16 countries. Among 
subjects aged 20-44 years, the median prevalence of chronic bronchitis was 2.6%, with wide 
variations across countries. Men were affected significantly more often than women, and 73% 
of those affected were current smokers (Cerveri et al. 2001). Similar questionnaires were sent 
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to subjects aged 45-69 years in Australia, where chronic bronchitis was reported by 12% 
(Abramson et al. 2002). A French population survey, where the mean age of participants was 
51.1 years, reported a chronic bronchitis prevalence of 4.1% (Huchon et al. 2002). The 
Copenhagen City Heart Study among men and women aged over 65 found chronic bronchitis 
prevalences of 19% and 13%, respectively (Lange et al. 2003). The World Health 
Organization (WHO) estimated the prevalence of chronic bronchitis to vary between 7% and 
17% across countries (Global Alliance against Chronic Respiratory Diseases 2007). These 
results reflect the geographic variation in chronic bronchitis as well as its increasing 
prevalence with age. Higher disease rates among men than women are mainly due to higher 
smoking prevalence among men (Cerveri et al. 2001); however, the sex-related differences in 
the prevalence of both chronic bronchitis and smoking are diminishing (Helakorpi, Prättälä & 
Uurtela 2008, Chilcoat 2009). 
 The prevalence of chronic bronchitis, similarly to that of smoking, has decreased 
considerably since the 1960s in Finland (Huhti 1965, Terho et al. 1987, Reijula et al. 1990, 
von Hertzen et al. 2000). In the 1990s, chronic bronchitis was estimated to affect 400 000 
subjects in Finland, equivalent to 10% of the adult population, with substantial regional and 
sex-related differences (Laitinen & Koskela 1999). The FinEsS study assessing prevalence 
rates and risk factors of airway disorders in Finland, Estonia, and Sweden, recently found the 
self-reported prevalence of chronic productive cough to be 12% in Helsinki and 11% in 
Lapland among 12 695 subjects aged 20-64 years. However, the prevalence of physician-
diagnosed chronic bronchitis was only 3.4% in Helsinki and 2.9% in Lapland (Kotaniemi et 
al. 2002). The prevalence of self-reported chronic bronchitis was significantly higher in 
northern Finland than in northern Sweden (7%), whereas the prevalence of physician-
diagnosed chronic bronchitis was higher in northern Sweden (Lindström et al. 2001). These 
numbers are in line with the view that chronic bronchitis is often underdiagnosed. 
 A 40-year cohort study in a Finnish rural population estimated the cumulative 
incidence of chronic bronchitis to be 42% in continuous smokers, 26% in former smokers, 
and 22% in never smokers. The symptoms were usually persistent in smokers, whereas 
temporary in others (Pelkonen et al. 2006). No other long-term studies exist on the incidence 
of chronic bronchitis, and the above-mentioned estimates were derived from a population 
where most of the subjects were farmers. 
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2.4.4. Effect on pulmonary function 
Smokers with chronic bronchitis have an excess risk for COPD relative to asymptomatic 
smokers (Lange et al. 2003, de Marco et al. 2007, Guerra et al. 2009). However, even without 
the development of COPD, chronic bronchitis can affect pulmonary function. Chronic 
productive cough increases the risk of asthma (Troisi et al. 1995, Huovinen et al. 1999) and 
shortness of breath in exercise (Kotaniemi et al. 2003). Chronic bronchitis has also been 
shown to be associated with decreased FEV1 values (Vestbo, Prescott & Lange 1996, 
Pelkonen et al. 2006, Pelkonen 2008, Eduard, Pearce & Douwes 2009) and an increased 
prevalence of obstructive sleep apnea (Larsson et al. 2001). The impairment of pulmonary 
function is, however, reversible and can be slowed down by smoking cessation (Willemse et 
al. 2004).  
2.4.5. Other health effects 
Chronic bronchitis is associated with poor quality of life (Doll et al. 2002), depression, and 
anxiety (Wagena et al. 2005). COPD patients with chronic bronchitis report more wheezing, 
nasal and ocular symptoms, and exacerbations than those without chronic bronchitis but with 
similar lung function (Kim et al. 2011). Chronic bronchitis increases the risk of coronary heart 
disease, and this association remains significant after the effect of smoking has been taken 
into account (Jousilahti et al. 1996). Chronic bronchitis is related to increased all-cause 
mortality, even in nonsmokers, in subjects aged <50 years, and in those without the presence 
of airflow obstruction (Lange et al. 2003, Pelkonen et al. 2006, Guerra et al. 2009). COPD 
patients who suffer from chronic bronchitis symptoms have a higher mortality risk than 
asymptomatic patients (Ekberg-Aronsson et al. 2005). 
2.5. Chronic obstructive pulmonary disease 
2.5.1. Definitions  
According to the Global Initiative for Obstructive Lung Disease (GOLD) guidelines and the 
common guidelines of American Thoracic Society (ATS) and European Respiratory Society 
(ERS), COPD is a “preventable and treatable disease with some extrapulmonary effects that 
may contribute to the severity in individual patients. Its pulmonary component is 
characterized by airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the lungs to noxious 
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particles or gases” (Celli, MacNee & ATS/ERS Task Force 2004, GOLD 2010). The clinical 
picture of the disease depends on whether the inflammation site is mainly in the small 
airways, leading to obstructive bronchiolitis, or in lung parenchyma, leading to emphysema. 
The airflow limitation is caused by a mixture of these pathological changes, and sometimes 
asthma or chronic bronchitis worsens the obstruction (Mannino & Buist 2007). 
 The common guidelines of GOLD, ATS, and ERS define COPD as post-
bronchodilator FEV1/FVC ratio < 0.70 in spirometry. The stage of the disease is determined 
by the value of FEV1, which is ≥80% of predicted in mild (stage I) COPD, ≥50% but <80% 
of predicted in moderate (stage II) COPD, and ≥30% but <50% of predicted in severe (stage 
III) COPD. In very severe (stage IV) COPD, the patient has an FEV1 <30% of predicted, or 
<50% plus chronic respiratory failure (GOLD 2010). Even though these criteria are widely 
used, they have been criticized because they seem to result in overdiagnosis in the elderly and 
underdiagnosis in young subjects (Hardie et al. 2002, Medbo & Melbye 2007). The British 
Thoracic Society (BTS) uses a criterion of FEV1<80% of predicted in addition to 
FEV1/FVC<0.7 to define COPD. Use of an additional criterion, FEV1<lower limit of normal 
(LLN) or FEV1<80% of expected, is increasingly recommended because it reduces age-
related biases and the number of false-positive diagnoses (Swanney et al. 2008, Vollmer et al. 
2009). The LLN cutoff is defined as being below the lower fifth percentile of a large healthy 
reference group. Calculating the LLN values, which take into account the subject’s age and 
height, thus requires availability of reliable reference equations. Using the LLN for 
FEV1/FVC instead of the fixed ratio<0.7 is also an acceptable way to avoid false-positive 
cases (Swanney et al. 2008). 
 Although reduced lung function is a common feature among COPD patients, several 
different phenotypes of the disease exist. The extent of airway inflammation and emphysema 
has long been known to vary among patients. However, the frequency of exacerbations, the 
severity of gas exchange impairment, and airway hyperresponsiveness, for example, also 
contribute to different COPD phenotypes. The expression of disease components among 
patients can be used to classify them into subgroups, or phenotypes, who respond to therapy 
in different ways. Researchers aim at identifying phenotypes that can be offered specific 
therapies (Han et al. 2010). 
30 
 
2.5.2. Risk factors  
Many environmental factors causing chronic bronchitis can eventually also result in COPD. 
The single most important cause of COPD is tobacco smoking, which accounts for about 75% 
of COPD-related mortality in Western countries. In countries with lower income, 40% of 
COPD mortality has been estimated to be caused by tobacco, exposure to biomass fuels being 
the major risk factor (Mannino & Buist 2007, Salvi & Barnes 2009). Airway 
hyperresponsiveness, childhood respiratory infections, and a family history of asthma are 
important risk factors of COPD, particularly among subjects aged under 45 years (de Marco 
et al. 2011). Occupational exposure to dusts and fumes, air pollution, and passive smoking 
may also contribute to the development of COPD (Mannino & Buist 2007). Occupational 
exposure has been estimated to account for 15% of the burden of COPD with, however, large 
regional variance (Balmes et al. 2003, Salvi & Barnes 2009). In Finland, the attributable 
fraction of occupational mortality of all COPD deaths was 12% when exposure to dust and 
welding fumes at work was examined (Nurminen & Karjalainen 2001). Exposure to dusts is 
common in, for example, farmers, and their mortality due to respiratory diseases has been 40-
50% higher than the average in Finland (Notkola, Husman & Laukkanen 1987). Physical 
activity in COPD patients can reduce mortality, but has no influence on disease progression 
(Chavannes et al. 2002, Garcia-Aymerich et al. 2007). Women seem to be more susceptible 
than men to the effects of smoking, resulting in more severe symptoms of COPD 
(Langhammer et al. 2003, Sorheim et al. 2010). Low educational and socioeconomic status 
are independent risk factors for COPD (Prescott, Lange & Vestbo 1999, Kanervisto et al. 
2011). 
2.5.3. Epidemiology of COPD 
Because COPD is rarely diagnosed in its early phase, national registries generally 
underestimate its prevalence. The WHO estimates that COPD affects 210 million people 
worldwide (Global Alliance against Chronic Respiratory Diseases 2007). Population studies 
using spirometry have estimated COPD prevalence to be 5-15% in Europe and in the US 
(Mannino et al. 2000, Pena et al. 2000, Lundbäck et al. 2003). A large study among various 
geographic sites reported the prevalence of GOLD stage II or higher COPD to be 10.1% 
among subjects aged ≥40 years (Buist et al. 2007), whereas the prevalence was 8.3% when 
using FEV1/FVC<LLN as the disease definition (Vollmer et al. 2009). In all studies, the 
31 
 
prevalence rates have been highest among elderly smokers, and the majority of disease cases 
have had no previous diagnosis of COPD. Reasons for the underdiagnosis of COPD include 
patients' adjustment to current symptoms as well as the lack of symptoms in the early disease 
phase. Moreover, an estimated 10% of COPD patients actually do not fulfill the spirometry 
criteria of COPD. This can occur if both FEV1 and FVC are reduced, and their ratio is normal 
(Wan et al. 2011). 
 Few studies have estimated the incidence of COPD diagnosed with spirometry. 
Among elderly subjects with respiratory symptoms, the ten-year cumulative incidence of 
COPD was reported to be 13.5% (Lindberg et al. 2005). Another study found the nine-year 
cumulative incidence of COPD to be 6.1% among adults aged 18-74 years, and the risk was 
10-fold greater among those aged over 45 years than in those younger than 45 years 
(Johannessen et al. 2005). Young age does not, however, protect against the disease; among 
subjects aged 20-44 years and with a normal lung function, a large international cohort found 
the ten-year cumulative incidence of COPD to be 2.8%. In that study, the cumulative 
incidence was 4.6% among those aged 40-44 years (de Marco et al. 2007). In Finland, the ten-
year cumulative incidence of COPD, defined as FEV1<60% of predicted, was 2.5% in a rural 
population of subjects aged 40-64 years (Huhti & Ikkala 1980). A 40-year follow-up study 
reported the cumulative incidence of COPD to be 32% among continuous smokers, 14% in 
former smokers, and 12% in never smokers (Pelkonen et al. 2006). 
 In the 1990s, 200 000 Finns (5% of the population) were estimated to suffer from 
symptomatic COPD, whereas the number of asymptomatic patients was unknown (Laitinen & 
Koskela 1999). One study using spirometry reported prevalence rates of 12.5% and 3.0% for 
elderly males and females, respectively (Isoaho et al. 1994). Recently, the FinEsS study 
estimated that the prevalence of COPD according to GOLD criteria was 9.4% in northern 
Finland (15.6% in men and 3.7% in women). By applying the BTS criteria, the prevalence 
decreased to 5.4%. (Kotaniemi, Sovijärvi & Lundbäck 2005). Of the affected subjects, less 
than 25% had been diagnosed previously, and only one-third reported chronic productive 
cough. Another recent Finnish study with a larger number of participants reported the 
prevalence of COPD, defined as FEV1/FVC<LLN, to be 4.3% and 3.1% among men and 
women, respectively, and the prevalence had not changed between 1980 and 2000 (Vasankari 
et al. 2010). Since the 1990s, hospitalizations due to COPD have decreased, while COPD-
related mortality has remained unchanged (Kinnula et al. 2011). 
32 
 
 Worldwide, COPD prevalence and related mortality are increasing rapidly, mainly due 
to increased smoking and use of biomass fuels in low- and middle-income countries. Both of 
these risk factors particularly affect women; today, women suffer from COPD almost as often 
as men (Global Alliance against Chronic Respiratory Diseases 2007, Salvi & Barnes 2009). In 
2004, COPD was the fourth leading cause of death worldwide, and the WHO predicts that it 
will become the third leading cause of mortality by 2030 (World Health Organization 2004). 
In high-income countries, COPD is the major chronic disease for which mortality is 
increasing. In the US, for instance, death rates from COPD have doubled between 1970 and 
2002 (Global Alliance against Chronic Respiratory Diseases 2007). 
2.5.4. Association between COPD and smoking patterns 
Previously, COPD was estimated to develop in 20-25% of smokers (Fletcher & Peto 1977, 
Mannino 2003). Due to underdiagnosis of COPD, these estimates are, however, too small 
(Rennard & Vestbo 2006, Mannino & Buist 2007). Recent studies have shown that the actual 
proportion of affected smokers is greater (Lundbäck et al. 2003, Lokke et al. 2006, Pelkonen 
et al. 2006).  
 Regarding pulmonary function, no safe level of smoking has been suggested to exist. 
Although significant and long-standing exposure to environmental tobacco smoke probably 
accounts for some of the COPD cases among never smokers (Yin et al. 2007), it remains 
unclear whether moderate levels of passive smoking can result in permanent airflow 
obstruction (Coultas 1998, U.S. Department of Health and Human Services 2006). Neither is 
there evidence that regular light smoking causes COPD. One study reported that cross-
sectionally measured light smoking among subjects aged over 45 years was associated with 
COPD by using the GOLD criteria; however, no association was found when FEV1<80% was 
considered as an additional criterion (Lundbäck et al. 2003). Reducing heavy smoking 
substantially may reduce mortality as well as slow down the decline of FEV1 in chronic 
bronchitis patients (Lange et al. 1989, Simmons et al. 2005, Pelkonen et al. 2006). 
Nevertheless, hardly any studies exist on the effect of smoking reduction on COPD 
development. Reducing heavy smoking by 50% does not change the risk for hospital 
admissions due to COPD (Godtfredsen et al. 2002). Early quitting, by contrast, may protect 
from COPD development (Lokke et al. 2006). 
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2.5.5. Health effects 
COPD patients often suffer from comorbidities, which are partly caused by aging and 
smoking and partly by the extrapulmonary effects of COPD itself (Agusti 2005). COPD 
patients are at increased risk for cardiovascular diseases, osteoporosis, diabetes, respiratory 
infections, and lung cancer (Young et al. 2009, GOLD 2010). Weight loss, nutritional 
abnormalities, and muscle waste are common extrapulmonary effects of COPD (Schols & 
Wouters 2000), causing disability and poor exercise performance. These effects have been 
suggested to be mediated by tissue hypoxia, oxidative stress, increased metabolic rate, and 
systemic inflammation (Agusti 2005). Increased serum C-reactive protein (CRP) levels and 
microalbuminuria have been detected in COPD patients (Han 2010). Psychiatric problems, 
such as depression (Hanania et al. 2011), sleep disorders, and anxiety (Eisner et al. 2010, 
GOLD 2010) are also associated with COPD.  
 In addition to comorbidities, exacerbations are another feature characteristic of COPD. 
Exacerbation is an acute worsening of the patient’s condition, usually characterized by 
increased respiratory and systemic symptoms and an increased need for medication 
(Rodriguez-Roisin 2000). Frequent and severe exacerbations are associated with poorer 
survival (Soler-Cataluna et al. 2005). Other predictors of mortality in COPD patients include 
dyspnea, exercise performance, and body mass index (BMI), whereas the degree of 
obstruction is only weakly associated with mortality risk (Celli 2010). 
2.5.6. Treatment of COPD 
Because the only way to slow down the progression of COPD in its early phase is to avoid 
exposure to risk factors, smoking cessation is the primary intervention in COPD. Among 
patients with chronic respiratory failure, long-term oxygen therapy increases survival. Use of 
noninvasive ventilation (NIV), positive or negative pressure to support breathing, is 
recommended in acute excerbations among patients with moderate or severe COPD. Use of 
NIV reduces dyspnea, length of hospitalizations, readmissions, and mortality (Celli, MacNee 
& ATS/ERS Task Force 2004, GOLD 2010). Medications may relieve symptoms, increase 
exercise capacity, and reduce the number of exacerbations, but cannot normalize the enhanced 
decline in lung function. Pharmacological treatment of COPD consists of inhaled 
anticholinergics and beta agonists, theophylline, and corticosteroids (Celli, MacNee & 
ATS/ERS Task Force 2004). 
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 Narrowing of the airways, caused by smooth muscle hyperplasia and an increase in 
connective tissue, is the main reason for airflow limitation in COPD. Loss of elastic recoil and 
alveoli destruction also contribute to the obstruction (Barnes et al. 2002). In COPD, the 
neuronal parasympathetic activity in the airways is pathologically enhanced, resulting in an 
excess release of acetylcholine. This contracts smooth muscle cells and increases mucus 
production and airway hyperresponsiveness (Belmonte 2005). Enhanced parasympathetic 
activity is the main reversible component of bronchoconstriction in COPD and has been 
treated with anticholinergic compounds for decades. Anticholinergics have few adverse 
effects and are well tolerated (Gross 2006). In Finland, there are currently two 
anticholinergics in use: short-acting ipratropium bromide and long-acting tiotropium bromide. 
Use of ipratropium peaked in the 1990s, but has now been largely replaced by the more 
effective tiotropium, which came onto the market in 2002. Patients with severe COPD have 
been eligible for a special reimbursement for tiotropium purchases since 2004. Oxitropium 
was withdrawn from the market in 2002 (Finnish Statistics on Medicines, 1995-2008). 
 The sympathetic nervous system controls airway smooth muscle tonus through beta2 
receptors. Beta2 agonists stimulate these receptors as well as decrease parasympathetic 
activity, resulting in smooth muscle relaxation (Tashkin & Fabbri 2010). Short-acting beta2 
agonists are used both alone and in combination with ipratropium to relieve acute symptoms. 
Long-acting beta2 agonists are used to treat stable COPD, however, they are not as effective 
as tiotropium (Rodrigo, Nannini & Rodriguez-Roisin 2008). Beta2 agonists’ usual adverse 
effects include palpitations and tremor (Tashkin & Fabbri 2010).  
International guidelines recommend using short-acting bronchodilators when needed 
for mild COPD, and adding a long-acting bronchodilator, either tiotropium or a beta2 agonist, 
to treatment when the disease progresses to stage II. Inhaled corticosteroids are recommended 
for those with frequent exacerbations (GOLD 2010). Finnish Current Care Guidelines for 
COPD treatment are similar, except that they recommend tiotropium over long-acting beta2 
agonists for COPD stage II-IV (Kinnula et al. 2009). A large randomized control study 
recently found that tiotropium is more effective than long-acting beta2 agonist in preventing 
exacerbations (Vogelmeier et al. 2011). 
Roflumilast is a new oral medication that is particularly effective in COPD patients 
suffering from chronic bronchitis (Rennard et al. 2011). It is used together with 
bronchodilators. In Finland, COPD patients with chronic bronchitis, frequent exacerbations, 
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and FEV1<50% have been eligible for a basic reimbursement for roflumilast purchases since 
2011.  
2.5.7. The Finnish medication reimbursement system 
Finland’s Social Insurance Institution (SII) contributes to patients’ medication purchases from 
a pharmacy. A basic reimbursement, covering 42% of medication price, is granted for all 
prescribed purchases. A special reimbursement to cover 72-100% of medication expenses can 
be allocated if the patient has been diagnosed by a specialist, and the disease fulfills certain 
severity criteria. In addition to the amount remaining, the patient pays a fixed deductible at 
the pharmacy. It is most economical to buy the maximum amount of the reimbursed drug, a 
three-month requirement, at one time because only one fixed deductible is paid irrespective of 
the number of medication refills (Martikainen & Rajaniemi 2002). The next purchase can be 
made when the previous amount has been almost depleted (The Social Insurance Institution of 
Finland 2010). Special reimbursement eligibilities have been allocated for asthma since 1973. 
In 1985, also other chronic obstructive lung diseases were included, with medications for 
severe COPD reimbursed. The percentage covered was 90% from 1985 to 1992, 80% during 
1993, 75% from 1994 to 2006, and 72% from 2007 onwards (Valtioneuvoston asetukset 
vaikeiksi ja pitkäaikaisiksi arvioitavista sairauksista, joiden lääkehoidon kustannuksista 
sairasvakuutuslain perusteella korvataan 72 tai 100 prosenttia). 
 Until 2007, a special reimbursement for COPD medications was allocated if the 
patient had an FEV1<40% of predicted, or arterial pCO2 constantly >6.5kPa (stage III-IV 
COPD). Since then, FEV1<50% was considered severe enough if the patient suffered from 
exacerbations during bronchodilator treatment. In the 2011 updated criteria, arterial pCO2 is 
no longer included. (Finland’s Social Insurance Institution 2010). The SII tracks 
reimbursement eligibilities and medications for asthma, COPD, and other obstructive lung 
diseases together (Laitinen & Koskela 1999), and has collected exact diagnoses only since 
2000. Before that, diagnoses were registered occasionally, and COPD was often diagnosed as 
‘emphysema’ or ‘chronic bronchitis’ (Kotaniemi 2006, Laitinen & Koskela 1999). 
2.5.8. Genetics of COPD 
AAT deficiency, identified in 1963, is the most important known genetic risk factor for 
COPD (Wan & Silverman 2009). It is caused by inheritance of two protease inhibitor 
deficiency alleles from the AAT gene locus on chromosome 14. The prevalence of AAT 
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deficiency is highest in Europe and North America, 1/2000-7000, accounting for 1-2% of 
COPD cases. Smokers with AAT deficiency usually develop severe COPD as young adults, 
whereas nonsmoker carriers may be asymptomatic (Barker et al. 1997, Wan & Silverman 
2009). Variants of the AAT encoding gene may explain why some subjects develop COPD 
more easily, although they are not deficiency allele carriers (Obeidat et al. 2011). Another 
common autosomal recessive disorder possibly associated with COPD is cystic fibrosis, the 
result of a mutation in the cystic fibrosis transmembrane conductance regulator gene. The 
disease causes bronchiectasis and chronic bacterial lung infections, which may predispose to 
COPD (Sandford, Weir & Pare 1997). In most subjects, however, the clinical picture of 
COPD is likely to arise from an interaction between multiple genes and environmental 
factors. 
Multiple candidate gene studies have found polymorphisms associated with COPD. 
Studies in large population samples, for instance, have demonstrated that matrix 
metalloproteinase gene (MMP12) (Hunninghake et al. 2009, Haq et al. 2011) and SERPINE2 
gene encoding thrombin, urokinase, and plasmin inhibitors (Zhu et al. 2007) are associated 
with COPD. MMP12 is produced in the lungs by macrophages. Its amount is known to 
increase due to smoking, whereas the role of the SERPINE2 gene in the lungs is unclear. 
However, the results of candidate gene studies are inconsistent, and meta-analyses have also 
produced discrepant findings (Hersh et al. 2005, Smolonska et al. 2009, Castaldi et al. 2010). 
SERPINA1 gene, encoding alpha-1-antitrypsin, remains the only known gene with a 
consistent and reliable association with COPD (Obeidat et al. 2011). 
GWAs have identified multiple genomic variants associated with COPD. Many such 
variants are associated also with lung function, e.g. those near the hedgehog interacting 
protein (HHIP) region (Pillai et al. 2009, Cho et al. 2010, Hancock et al. 2010, Repapi et al. 
2010). By testing the multiple SNPs previously identified as associating with FEV1 and 
FEV1/FVC (Wilk et al. 2009, Hancock et al. 2010, Repapi et al. 2010), a recent meta-analysis 
found that three loci in chromosomes 4, 5, and 6 were associated also with COPD 
susceptibility (Castaldi et al. 2011). Variants in the nAChR gene on chromosome 15, in turn, 
are associated with COPD, lung cancer, and emphysema (Pillai et al. 2009, Lambrechts et al. 
2010) as well as with nicotine dependence and smoking behavior (Thorgeirsson et al. 2010). 
A cohort study found that after adjustment for smoking, the nAChR polymorphisms 
independently increased the risk of all these tobacco-related diseases (Kaur-Knudsen et al. 
2011). One possible explanation for this is that the receptor gene variants increase the 
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cholinergic activity in the lungs, resulting in excess mucus production, smooth muscle 
contraction, and perhaps also inflammatory cell recruitment (Wessler, Kirkpatrick & Racke 
1998).  
COPD prevalence is increased in subjects with lung cancer, regardless of smoking 
status and history of pack-years (Young et al. 2009). The inflammatory and immune-
modulating pathways seem to be similar in these diseases (Young & Hopkins 2011). A 
variant in chromosome 5, previously reported to be associated with lung cancer, was recently 
found to also be associated with airflow limitation and emphysema independent of smoking 
(Wauters et al. 2011), supporting the view that these pulmonary diseases share some common 
genetic background. 
 The newly identified susceptibility loci explain only a small proportion of the genetics 
of COPD. Individual susceptibility for the disease cannot be tested, and smoking remains the 
most important preventable risk factor for COPD. However, new discoveries may provide 
novel insights into disease pathophysiology. It is possible that ‘susceptible smokers’ are the 
ones who carry these risk alleles in their genome. 
2.6. Summary 
Although the associations of moderate and heavy smoking with chronic bronchitis and COPD 
are well established, studies on the pulmonary effects of reduced smoking, light smoking, and 
other low-rate smoking patterns are few. Light and occasional smoking are increasing in 
many countries, however, the phenomenon of light smoking has not been investigated earlier 
in a Finnish population. Finnish health surveys have shown that smokers consume on average 
less cigarettes daily than earlier. Also the proportion of former smokers is increasing. When 
examining the health effects of different low-rate smoking patterns, a longitudinal study 
design is an advantage, allowing observation of changes in smoking patterns and subsequent 
disease development rates. 
COPD is defined as a decreased lung function, with lung function also being an 
important independent marker of increased morbidity and mortality. Lung function declines 
physiologically throughout adulthood, and COPD incidence accumulates in older age. In 
addition to environmental factors that predispose to COPD, multiple other determinants affect 
lung function. Recent research has identified genetic variants associated with both lung 
function and COPD. However, the proportions of genetic and environmental factors affecting 
lung function vary across time and populations. The heritability of lung function has not been 
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evaluated earlier in a Finnish population, nor has it been assessed longitudinally or by 
excluding the effect of smoking.  
The trend to reduced smoking patterns potentially has a high public health impact. 
Because COPD morbidity is increasing globally, and the pulmonary effects of such smoking 
patterns are partly unknown, research on this subject at a population level is warranted. 
Further, as COPD manifests as decreased lung function, understanding the genetic and 
environmental determinants of lung function helps to target interventions to prevent COPD. 
Moreover, recognizing factors that support maintenance of good lung function might also 
help to prevent excess morbidity and mortality. 
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3. Aims of the study 
The aim of this thesis was to investigate longitudinal smoking patterns, especially light 
smoking and various changing smoking patterns, and their associations with pulmonary 
diseases. In addition, this study aimed to assess genetic and environmental factors 
independent of smoking that influence lung function. The main aim was to demonstrate that 
regarding pulmonary morbidity no safe level of smoking exists. Specific aims of this thesis 
were as follows: 
1. To investigate the prevalence and consistency of different smoking patterns in a 
Finnish population by focusing on the subgroup of daily light smokers, and to 
evaluate the characteristics of Finnish light smokers (Study I). 
2. To explore the heritability of lung function with repeated spirometry 
measurements by excluding the effect of smoking (Study III). 
3. To estimate the incidence and risk of chronic bronchitis according to various 
smoking patterns by taking into account changes in smoking behaviors over a 6-
year period (Study II). 
4. To estimate the incidence and risk of COPD over a 27-year follow-up according to 
changes in smoking patterns over a 6-year period (Study IV). 
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4. Methods 
4.1. Participants 
4.1.1. The Older Finnish Twin Cohort 
The Older Finnish Twin Cohort was established in 1974 to examine the genetic, 
environmental, and psychosocial determinants of health behaviors and chronic diseases. The 
cohort was compiled from the Central Population Registry by identifying as twin candidates 
sets of persons born on the same day, with the same surname at birth, of the same sex, and 
born in the same local municipality. The cohort included virtually all same-sex twin pairs 
born in Finland before 1958 with both members still alive in 1967 (Kaprio & Koskenvuo 
2002). Questionnaires were distributed in 1975, 1981, and 1990, with response rates of 89%, 
84%, and 77%, respectively. The 1981 questionnaire was delivered to all twins still alive in 
the cohort, whereas in 1990 the questionnaire was sent only to pairs born in 1930-1957, with 
both co-twins resident in Finland in 1987, if they had replied to at least one of the previous 
surveys. Data on subjects who participated in both the 1975 and 1981 surveys (n=21 609) 
were used in Studies I, II, and IV. Of these subjects, 11 015 participated again in 1990, and 
also data from this measurement point were used in Studies I and II. 
4.1.2. The FITSA substudy 
The Finnish Twin Study on Aging (FITSA) is a study of genetic and environmental effects on 
the disablement process in older female twins. The participants were recruited from the older 
Finnish Twin Cohort on the basis of age, sex, and zygosity (Tiainen et al. 2004). Invitations 
were sent in the year 2000 to 414 female twin pairs (178 MZ pairs, 212 DZ pairs, and 24 pairs 
of unknown zygosity, XZ) born in 1924-1937. Inclusion criteria were the willingness of both 
individuals in the pair to participate, ability to walk 2 km, and ability to travel independently 
to the research center. Eventually, 217 twin pairs (98 MZ, 106 DZ, and 13 XZ pairs) 
participated in the laboratory examinations and filled in questionnaires. At the follow-up in 
2003, all baseline participants were invited to participate, and individual twins could attend 
even if their co-twins refused. In 2003, 419 individuals completed questionnaires and 313 
participated in the laboratory measurements. Among never-smoking participants (n=374), 
those who attended spirometry at least at baseline (n=339) composed the sample of Study III. 
The attendance rates of never smokers in the FITSA study are described in Figure 1. 
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Figure 1. Participation rates of never smokers in the FITSA study.  
 
4.2. Measurements 
4.2.1. Smoking patterns 
4.2.1.1. Twin cohort questionnaires 
In the 1975 and 1981 questionnaires, smoking status was defined with a series of questions. 
Figure 2 presents the classification of smoking status and the exact questions asked. Never 
smokers were first separated from ever smokers and then occasional and former smokers were 
identified. Those who were classified as current smokers responded also to the question 
defining average daily cigarette consumption: ‘‘How many cigarettes do you smoke daily on 
average?’’ Former smokers were asked how old they were when they quit smoking and how 
many cigarettes they used to smoke daily. The amount categories were as follows: <5, 5–9, 
10–14, 15–19, 20–24, 25–39, and >40. In this study, 1975 and 1981 current smokers were 
further collapsed into three groups: daily light (<5 CPD), daily moderate (5-19 CPD), and 
daily heavy (≥20 CPD) smokers. The term ‘low-rate smoking patterns’ includes in this thesis 
both light and occasional smoking. 
The Finnish Twin Cohort:  
Female twin pairs born in 1924-1937 (n=1260 pairs) 
Laboratory measurements in 2000: 
374 never smokers (172 MZ, 202 DZ) 
Spirometry conducted in 2000: 
339 never smokers (157 MZ, 182 DZ) 
Laboratory measurements in 2003: 
276 never smokers (132 MZ, 144 DZ) 
Spirometry conducted in 2003: 
252 never smokers (119 MZ, 133 DZ) 
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Figure 2. Definition of smoking status in the twin cohort questionnaires in 1975, 1981, and 1990. 
 
More detailed smoking subgroups were formed according to the change in smoking 
status between 1975 and 1981. In Study I, only baseline light smokers were divided into 
subgroups, whereas in Studies II and IV all 1975-1981 participants were categorized 
according to change in their smoking patterns. See Statistical methods and Figure 3 for 
details. Formation of the smoking subgroups used in Studies II and IV is detailed in Appendix 
1.
 
Have you ever smoked 
more than 5-10 packs 
of cigarettes in your 
lifetime? 
Do you smoke or have 
you smoked cigarettes 
regularly, say daily, or 
almost daily during your 
lifetime? 
Do you still 
smoke 
NO 
YES YES 
Never smokers Occasional smokers 
NO NO 
Former smokers 
YES 
Current smokers
Figure 3. Smoking subgroup classification and proportions of different subgroups used in Study II (on the right) and in 
Study IV (on the left). Subgroups with similar smoking habits are presented with the same color. Detailed formation of 
the subgroups is presented in Appendix 1. 
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4.2.1.2. Questionnaires of the FITSA study 
In the FITSA study, smoking status was assessed in the 2000 and 2003 questionnaires by 
asking: “Have you ever smoked more than 5-10 packs of cigarettes?” Negatively responding 
subjects were considered never smokers (n=374, 86% of the study population). Current 
smoking was also defined in the questionnaire, and none of those declaring themselves as 
never smokers reported current smoking. 
4.2.2. Chronic bronchitis 
Chronic bronchitis was assessed in the 1975 and 1981 questionnaires by asking whether 
subjects suffered from chronic cough and mucus production from the airways. Respiratory 
symptoms were monitored with the MRC series of questions (British Medical Research 
Council 1960), by asking: “Do you regularly for extended periods of time have a cough?”, 
“How many months in a row do you cough per year?”, “For how many months in a row do 
you bring up phlegm from your chest per year?”. Those reporting suffering from the 
symptoms over at least three successive months a year were considered to have chronic 
bronchitis. Questions were asked identically in both surveys, and chronic bronchitis was 
dichotomized as 0 or 1. Chronic bronchitis was the main outcome in Study II, and it was used 
as a potential confounder in Study IV. 
4.2.3. COPD 
To define COPD, a record-linkage study was performed by combining the data of the 1975 
and 1981 twin cohort surveys with the SII’s nationwide medical registry data. Data of 
diagnoses entitling to special reimbursements (between 1981 and 2008) as well as data on 
purchased basically reimbursed medications (1995-2008) were obtained for those 21 609 
subjects who participated in both 1975 and 1981. Because inhaled anticholinergics and 
combinations of inhaled anticholinergics and beta2 agonists are generally not used to treat 
conditions other than COPD, purchase dates of such medications were monitored. These 
medications included oxitropium, ipratropium, and tiotropium, as well as combinations of 
ipratropium and salbutamol, and ipratropium and fenoterol. A similar definition of COPD has 
been used previously (Tynkkynen et al. 2009). 
 In this study, COPD was defined as a diagnosis of emphysema, chronic bronchitis, or 
COPD entitling to special reimbursement, or as regular usage of inhaled anticholinergics 
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preparations. Regular usage was considered to be at least two purchases at 99-day intervals. 
Subjects who moved abroad, were deceased, or had a special reimbursement for COPD, 
chronic bronchitis, or emphysema before the start of the follow-up were excluded from the 
analyses.  
4.2.4. Lung function 
Lung function of the FITSA study participants was assessed with spirometry measures in 
2000 and 2003 by using an electronic spirometer (Medikro 202, Medikro Co., Kuopio, 
Finland). At baseline, 397 subjects provided acceptable spirometry performances, and of 
these, 339 were never smokers and were included in our study. At follow-up, 287 subjects, 
252 of whom were never smokers, provided adequate performances.  
Flow-volume spirometry, including all values except post-bronchodilator measures, 
was performed according to international guidelines (Miller et al. 2005b). Trained laboratory 
nurses made the measurements and guided the participants. The subjects were asked to inhale 
maximally and to exhale into a mouthpiece connected to a flow transducer. Slow and fast 
expiratory maneuvers were practiced before actual measurements. Spirometry was performed 
in a standing position, and subjects sat down after each performance. Maneuvers were 
performed until at least two were acceptable, and of these, the better one was recorded as the 
subject's result. Nose clips were used, and if the testee had dentures, spirometry was carried 
out without them. The spirometer was calibrated daily and was accurate to within 1%. Age- 
and height-adjusted reference values were derived from a national sample, recommended to 
be used in Finns (Viljanen 1982, Sovijärvi et al. 2006). In Study III, FEV1, FVC, and 
FEV1/FVC ratio measurements derived from both time-points were analyzed as continuous 
variables. 
4.2.5. Potential confounders 
A confounding variable is an extraneous factor that is statistically related both to the outcome 
and to the exposure. To control for such factors in this study, the final statistical models 
investigating the association between the exposure and the outcome were adjusted for 
multiple potential confounders. Known confounding factors from the literature were taken 
into consideration, if data were available. The effects of other potential confounders were 
tested by adding such variables in the statistical model. If a potential confounding variable 
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changed the observed risk estimates in the model, it was included in the final multivariate 
model.  
4.2.5.1. Twin cohort variables 
The 1975 and 1981 questionnaires were composed of an extensive battery of questions 
concerning health, health behavior, and sociodemographic factors. In Studies I, II, and IV, the 
variables age, sex, alcohol use, physical activity, and the age at smoking initiation were used 
as potential confounders. In addition, marital status, pipe and cigar smoking, inhalation 
pattern, coffee and tea drinking, life satisfaction, and stress of daily activities were adjusted 
for in Study I. Education was adjusted for in Studies I and IV. Asthma and pack-years were 
used in Studies II and IV, and allergic rhinitis and occupation in Study II. The variable 
‘duration of cessation’ (among former smokers) was created and used in Studies II and IV. 
 Age was used as a continuous variable, and in Study I, was also categorized into four 
groups: ≤25, 26-30, 31-40, and >40 years. Alcohol use was regarded as ‘heavy’ if the 
participant reported having six or more drinks on one occasion at least monthly (Kaprio et al. 
1987). Physical activity was categorized as sedentary, intermediate, or active based on 
frequency, duration, and intensity of physical activity (Kujala, Kaprio & Koskenvuo 2002). 
Daily coffee and tea drinking were assessed as continuous variables by the number of cups 
per day. 
 The variable ’pack-years’ was calculated according to average daily cigarette 
consumption and age at regular smoking initiation. According to the age at smoking 
cessation, duration of cessation was categorized in Study II as >10, 2-10, and <2 years, and in 
Study IV as >10, 5-10, and <5 years. Current and former smokers were asked whether or not 
they inhaled smoke while smoking. Reporting having ever smoked at least 50 cigars or 75 
cigarillos, or more than 3-5 packages of pipe tobacco, was considered as lifetime pipe/cigar 
smoking. Self-reported age at regular smoking initiation was used as a continuous variable.  
Education was dichotomized as those with at least senior high school completed and 
those with lower education. Marital status was coded in the questionnaire as unmarried / 
married / remarried / living with a partner / divorced / widowed. In Study I, those who were 
single in 1975 were used as a reference group, those married or living with a partner formed 
another group, and those separated or widowed composed the third group. Occupation was 
coded as upper-level employee or large entrepreneur / lower-level employee or small 
entrepreneur / trained worker / untrained worker / farmer, fisher, or gardener / unknown. 
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Asthma and allergic rhinitis were screened by asking “Has your doctor ever told you 
that you have asthma/allergic rhinitis?” Life satisfaction was assessed by a four-item scale 
focusing on feelings of loneliness, hardness of life, happiness, and anhedonia (Koivumaa-
Honkanen et al. 2004). Being tense and nervous, having stress in daily activities, being 
mentally and physically exhausted at the end of the day, and daily activities being extremely 
trying and stressful were reported by subjects on a scale from 1 to 4 (Reeder, Schrama & 
Dirken 1973), and the total score (4-16) was used to define stress of daily activities (Korkeila 
et al. 1998). 
4.2.5.2. Variables of the FITSA study 
The general questionnaire of the FITSA study included in both years 189 questions 
concerning sociodemographic factors and health behavior. In addition, a separate health 
questionnaire included over 200 specific questions concerning health. Pulmonary diseases, 
BMI, height, physical activity, and occupation were examined as possible covariates. Weight 
and height were measured in the laboratory, and BMI was calculated as a function of weight 
and height (kg/m2). 
Pulmonary morbidity was screened by asking whether one suffered from chronic 
cough or sputum production, or chronic bronchitis, chronic or seasonal asthma, emphysema, 
or other pulmonary diseases, such as tuberculosis, alveolitis, bronchitis, pneumothorax, 
pneumonia, embolus, sarcoidosis, pleural effusion, fibrosis, allergy, or chronic obstructive 
pulmonary disease. A dichotomous variable describing lung health was created, which was 
coded as 1 if the participant reported suffering from any of the above-mentioned disorders. 
Leisure-time physical activity was scaled in the questionnaire as following: No 
leisure-time physical activity (0), light walking 1-2 (1) or several times (2) a week, moderate 
activity 1-2 (3) or several times (4) a week, vigorous activity (5), and competitive sports (6). 
Subjects in categories 0 and 1 were considered as sedentary, 2-3 as engaging in moderate 
activity, and 4-6 as engaging in high activity (Schroll 2003). 
4.3. Statistical methods 
4.3.1. Individual-based analyses 
In Studies I, II, and IV, the twins were analyzed mostly as individuals. Statistical analyses 
were performed with Stata statistical software (versions 9-11), where the possible correlation 
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between twin individuals can be controlled for by using the cluster option and robust 
estimators of variance (StataCorp. 2009).  
For Studies I, II, and IV, smoking subgroups taking into account changes that occurred 
in smoking patterns between 1975 and 1981 were formed. In Study I, future smoking patterns 
of the 1975 light smokers were analyzed, and three groups were formed according to their 
consumption in 1981 (increasers, quitters, continuous light smokers). In Study II, more 
detailed subgroups were formed, and categories with similar changes in smoking patterns 
were grouped together (Figure 3). In Study IV, the disease risks for the initial 36 smoking 
categories were first explored with regression models, and then the categories for which risk 
estimates could be set as equal in the regression model were combined (Figure 3).  
The associations between possible confounding factors and outcomes were explored in 
Studies II and IV with logistic regressions, and in Study III with linear regression models 
before proceeding to genetic modeling. Correlations between confounders were also assessed; 
in Studies II and IV, some potential confounders (smoking initiation age, pack-years) were 
excluded from the final models because of their high correlation with smoking categories 
(≥0.6).  
Adjusted logistic regression models were used in Studies I, II, and IV, and odds ratios 
(ORs) with 95% confidence intervals (CIs) were computed for the outcomes. In Study I, 
logistic regressions were used to test the statistical significances of being a light versus a 
heavy smoker and to examine longitudinally the predictors for continuing light smoking 
versus increasing smoking or quitting during the follow-up. In Studies II and IV, the risks for 
incident chronic bronchitis and COPD were tested with logistic regressions among different 
smoking categories, also among subgroups taking into account the changes in smoking 
patterns between 1975 and 1981. Never smokers were used as the reference group (OR=1.00). 
In Study II, further analyses were performed with random-effects logistic regression 
models after reshaping the data as longitudinal panel data, consisting of repeated measures of 
smoking and chronic bronchitis. The random-effects model analyzed the risk of chronic 
bronchitis associated with smoking patterns at all measurement points simultaneously by 
assuming that subject’s smoking status at certain measurement point is independent of other 
measurements (Diggle et al. 2002, Twisk 2003). 
 Survival analyses were used in Study IV when exploring the risk of developing COPD 
during follow-up. The risks were estimated according to smoking status in 1981, as well as 
according to changes in smoking patterns between 1975 and 1981. Because follow-up times 
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were different for special reimbursement eligibilities (1981-2008) and inhaled anticholinergic 
purchases (1995-2008), analyses were performed separately for both outcomes (study design 
presented in Figure 4). The follow-up for individuals ended on the date of granting a special 
reimbursement / initiation of regular medication use, or migration from Finland, death, or end 
of the follow-up. Hazard ratios (HRs) with 95% CIs for COPD development were calculated 
with an adjusted Cox proportional hazards regression model (Cox & Oakes 1984). 
Nonparametric Nelson-Aalen estimators were used when illustrating the cumulative hazard 
estimates for COPD for 1981 smoking groups. 
 
 
 
 
Figure 4. Design of the Study IV. Smoking was measured in 1975 and 1981.The follow-up for special 
reimbursement eligilibilities started in 1981, and the follow-up for anticholinergic medication in 1995. Both follow-
ups ended in 2008. 
 
4.3.2. Models based on twin pairs 
4.3.2.1. Discordant twin pair analyses, Studies II and IV 
Because MZ twins share 100% of their genes, and DZ twins share on average 50% of their 
segregating genes, greater resemblance between twins of a MZ pair is considered to be due to 
genetic influences. Accordingly, a disease affecting only one twin of a MZ pair must be 
caused by unique environmental factors. Same-sex MZ twin pairs discordant for an outcome 
phenotype are excellent for case-control studies since they are perfectly matched for 
genotype, sex, age and shared environmental influences (Boomsma, Busjahn & Peltonen 
2002). Causal relationships between outcome phenotypes and associated risk factors can also 
be tested with discordant twin pairs. If the association observed in individual-based analysis 
remains significant in discordant MZ twin pairs, genetic and shared environmental factors 
affecting this association can be ruled out.  
Exposure Follow-up for special reimbursements 
Follow-up for 
anticholinergics 
End of follow-up 
1975 1981 1995 
2008 
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In Study II, twin pairs discordant for smoking status in 1975-1981 and for the 
incidence of chronic bronchitis in 1990 were analyzed (n=15 pairs). The twin with chronic 
bronchitis was the case, and the healthy co-twin was the control. Twins were considered 
discordant for smoking if one twin was a never smoker, and the co-twin a persistent or 
recurrent smoker. The ORs were calculated by the ratio of the number of case-control pairs in 
which the case smokes and the control does not smoke to the number of pairs in which the 
case does not smoke while the control smokes. The significance of the association within such 
pairs was tested with McNemar’s test (Thomas 2004). 
 In Study IV, conditional logistic regression analyses were conducted for MZ and DZ 
twin pairs discordant for COPD (n=325; 213 DZ, 81 MZ pairs). The risk estimates related to 
smoking patterns were assumed to remain similar to those found in the whole sample, which 
would support a causal association between smoking and COPD, independent of genetic 
factors.  
4.3.2.2. Quantitative genetic modeling, Study III 
All analyses in Study III, except the initial models testing confounders, were based on the 
twinship of the study subjects. Correlations were calculated with Stata, whereas uni- and 
multivariate structural equation modeling (SEM) was implemented in Mx software and based 
on standard Mx scripts obtained from the GenomEUtwin Mx website 
(http://www.psy.vu.nl/mxbib/).  
The classical twin design is based on the assumption that the phenotypic variance can 
be decomposed into additive genetic (A), dominant genetic (D) or shared environmental (C), 
and nonshared environmental (E) factors. The expected correlations for variance components 
A, D, and C between the twins of a MZ pair are 1.0, while for DZ pairs, the correlations are 
0.5 for A, 0.25 for D, and 1.0 for C. E effects are, by definition, uncorrelated in both MZ and 
DZ twins. E also contains random effects and is therefore always included in the models. 
Further, correct estimation of genetic and environmental components requires that no GxE 
interaction, gene-environment (GE) correlation, or assortative mating exists. Estimation of 
GxE interaction and GE correlation requires special models. Also an assumption of equal 
environmental effects for MZ and DZ twins is required for the reliable estimation of variance 
components (Posthuma et al. 2003). 
In Study III, intra-class correlation coefficients with 95% CIs were first computed for 
FEV1, FVC, and FEV1/FVC in MZ and DZ twin pairs to estimate the within-pair similarity. 
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Greater similarity between MZ than DZ pairs is suggestive of a genetic influence on the trait. 
Then, for each lung function parameter, cross-twin, cross-time correlations were computed for 
MZ and DZ pairs. A correlation between baseline measures in one twin and follow-up 
measures in the co-twin gives evidence whether shared genetic influences explain the 
covariance in the trait over time. 
By SEM, the variance in the observed phenotype can be decomposed into A, E, and 
either C or D components simultaneously. The mathematical models may also be represented 
by using path diagrams (see Figure 5) (Evans, Gillespie & Martin 2002). The basic 
assumptions of genetic modeling (equal means and variances for MZ and DZ twins) are tested 
by comparing the genetic models with saturated models, which make no such assumptions. If 
the fit of genetic models to the data is not significantly worse than that of saturated models, it 
means that these assumptions are fulfilled. SEM is based on comparing simplified models 
with the model in which they are nested. Starting with a full ACE or ADE model, variance 
components are dropped one at a time, and the fit of simplified models (AE, CE, E) to the 
data is tested. The aim is to obtain the most parsimonious and best-fitting model to explain the 
observed pattern of similarity in MZ and DZ pairs (Boomsma, Busjahn & Peltonen 2002). 
Likelihood ratio tests and Akaike’s Information Criterion (AIC) are used to compare 
alternative models, whereas χ2- and p-values are applied to compare nested submodels with 
the more saturated ones (Neale & Maes 2006). In Study III, univariate models were used to 
test the associations of covariates with lung function phenotypes (see path diagram in Figure 5 
as an example of a univariate ACE model). 
 The univariate model can be extended to a multivariate model when more than one 
measurement per subject is available. Such models give evidence of whether genetic effects 
are shared by repeated measurements or whether they are specific to a certain measurement 
point. Since spirometry was performed at two time-points, a bivariate Cholesky 
decomposition (Posthuma et al. 2003) (Figure 6) was used to explore the data. In such an 
ACE or ADE model, effects A1, C1, D1, and E1 are common to baseline and follow-up, while 
A2, C2, D2, and E2 load only on the later measurement point. Heritability estimate of the 
phenotype is the fraction of genetic variance from the total variance. Variances are derived by 
squaring the path (standard) coefficients x, y, and z of the latent variables A, D or C, and E. 
The phenotypic variance for the trait thus equals x2 + y2 + z2 (Boomsma, Busjahn & Peltonen 
2002). 
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Figure 5. Univariate twin model illustrating the similarity of a trait (FEV1) in a MZ or DZ twin pair. The variance in 
the trait is composed of latent variables A, C, E, and x, y, and z represent the respective path coefficients on the 
trait. The variance in the phenotype also equals x2+y2+z2. The path coefficients can be regarded as standardized 
regression coefficients. An ADE model would include D effects instead of C; C and D effects cannot be estimated 
simultaneously as they are confounded. 
 
 
 
 
 
 
 
Figure 6. A bivariate ACE Cholesky model illustrating genetic and environmental effects loading on two 
measurement points of FEV1 in one twin. Effects A1, C1, and E1 are common to both measurement points, 
whereas A2, C2, and E2 load only on the later measurement. The alternative model would include effect D instead 
of C. 
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5. Results 
5.1. Various smoking patterns 
5.1.1. Prevalence of different smoking patterns in 1975-1981 
Proportions of different smoking status groups for the 21 609 subjects who participated both 
in 1975 and 1981 are shown in two columns in Figure 1. In 1975, 31.5% of subjects were 
current smokers, and, according to daily smoking amount, were grouped as light (8.1%), 
moderate (67%), and heavy smokers (25%); representing 2.5%, 21%, and 8% of the total 
population, respectively (Figure 7).  
By 1981, the proportion of former smokers in the sample had increased (from 16.4% 
to 21.2%), that of moderate smokers had decreased (from 21% to 16.7%), and that of other 
smoking groups had remained rather stable (Figure 7). The majority of former, moderate, and 
heavy smokers reported a similar status also in 1981 (73%, 56%, and 61%) (not shown in 
Figure 7). However, light smoking showed a less consistent smoking pattern at follow-up. 
The 1981 smoking patterns of the baseline (1975) light smokers are described in Figure 7, 
where almost half had quit smoking, about one-fifth had increased to heavy or moderate 
smoking, and almost one-third had continued light smoking. 
  
Figure 7. Proportions of different smoking status groups among the study population in 1975 and 1981, and the 
distribution of baseline light smokers according to smoking status in 1981 (increasers, 22%; continuous light 
smokers, 29%; quitters, 49%). Note: The percentages have been rounded and do not sum exactly 100%. 
29% 
49% 
22% 
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When taking into account smoking status at both time-points and examining the 
smoking subgroups describing change in smoking in 1975-1981, constant never smokers 
comprised half of the study population, whereas constant moderate smokers, constant former 
smokers, and quitters comprised about one-tenth each. Other smoking subgroups, e.g. 
decreasers, increasers, and relapsed former smokers, were relatively smaller (see Figure 3 in 
Methods for details).  
5.1.2. Consistency of light smoking 
The 1981 smoking patterns of the baseline (1975) light smokers are presented in Figure 7. 
About half of the 1975 light smokers attended again in 1990, when 53% reported being 
former, 33% moderate / heavy, and 14% light smokers. At a population level, the share of 
light smokers remained quite stable: 8.0% and 8.2% of current smokers reported consuming 
1-4 CPD in 1981 and 1990. Only 5.9% of the baseline light smokers reported the same 
consumption throughout the 15 years; smoking reducers, initiators, and relapsed former 
smokers formed new members in the group of light smokers (see Figure 8). 
 
Smoking status 1981 among 1990 light 
smokers
Never / occasional
smokers
Light smokers
Former smokers
Moderate/heavy
smokers
Figure 8. Previous smoking status of those who reported being light smokers in 1981 and 1990. 
 
5.1.3. Characteristics of light smokers  
Characteristics of the 1975 light smokers were compared with heavy smokers by using age- 
and sex-adjusted logistic regressions. The likelihood of light versus heavy smoking was 
elevated among women, physically active and better educated subjects, tea drinkers, those 
Smoking status 1975 among 1981 light 
smokers
Never / occasional
smokers
Light smokers
Former smokers
Moderate/heavy
smokers
Smoking status in 1975 among the 1981 light 
s okers 
Smoking status in 1981 among the 1990 light 
smokers 
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reporting older age at smoking initiation, and those reporting less stress. The likelihood of 
light smoking was lower among older smokers, lifetime pipe/cigar smokers, coffee drinkers, 
those ever married or living with a partner, and those reporting inhalation of tobacco smoke, 
heavy alcohol use, or dissatisfaction with life. 
 Baseline light smokers were divided into groups according to their smoking patterns in 
1981 (increased, quit, or continued light smoking). Associations between their other 
characteristics at baseline and 1981 smoking patterns were studied. Baseline age of 26-30 or 
≥40 years predicted continued light smoking versus quitting, whereas being single in 1975 but 
living with a partner in 1981 predicted change in smoking. Higher education at baseline 
predicted continued light smoking versus increasing smoking, whereas heavy alcohol use at 
baseline predicted the opposite pattern.  
5.2. Heritability of lung function 
5.2.1. Lung function and characteristics of the FITSA participants 
Among never-smoking participants, the mean age at baseline was 68.7 years and the lifetime 
pulmonary disease prevalence was 20%. Over half of these female subjects reporting 
pulmonary diseases suffered from asthma (59% at baseline, 64% at follow-up), the second 
most common lung disease being chronic bronchitis, respectively (14% and 11%). Mean 
spirometry values of those never smokers who attended measurements at both time-points are 
presented in Table 1. 
Table 1. Mean spirometry values of the never-smoking MZ and DZ participants of the FITSA study. 
 FEV1 (MZ) FEV1 (DZ) FVC (MZ) FVC (DZ) FEV1/FVC (MZ) 
FEV1/FVC 
(DZ) 
Mean value (liters or 
%) with (SD) in 2000 2.29 (0.47) 2.18 (0.49) 2.91 (0.57) 2.76 (0.61) 73.22 (8.23) 75.44 (9.40) 
Mean value (liters or 
%) with (SD) in 2003 2.22 (0.46) 2.14 (0.44) 2.77 (0.58) 2.70 (0.56) 77.91 (6.52) 76.90 (7.60) 
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5.2.2. Lung function correlations 
The ICCs (see Table 1 in Study III) were greater for MZ than DZ pairs, suggesting a genetic 
background in the observed variance in FEV1, FVC, and the FEV1/FVC ratio. Only the ICCs 
for FEV1/FVC at follow-up did not differ between MZ and DZ pairs.  
Cross-twin, cross-time correlations for FVC are presented in Table 2 (see results for 
FEV1 in Table 2, Study III). The correlation of FVC 2000 of twin 1 and FVC 2003 of twin 2 
was 0.52 among MZ pairs and 0.40 among DZ pairs, suggesting that the same genes would 
affect that phenotype at both measurement points. 
Table 2. Correlations between FVC in 2000 and in 2003 in MZ and DZ never-smoking twin 
pairs. Correlations for MZ pairs are in bold; those for DZ pairs in italics. 
 Twin 1 Twin 2 
 FVC in 2000 
FVC in 
2003 
FVC in 
2000 FVC in 2003 
Twin 1  
- 
 
0.79 
 
0.71 
 
0.52 FVC in 2000 
FVC in 2003 0.75 - 0.51 0.44 
Twin 2  
0.25 
 
0.18 
 
- 
 
0.81 FVC in 2000 
FVC in 2003 0.40 0.36 0.70 - 
 
5.2.3. Genetic and environmental influences on FEV1, FVC, and 
FEV1/FVC 
Covariates for bivariate modeling were chosen according to the results of the linear regression 
models and univariate genetic models. The model for FEV1 was adjusted for age, BMI, 
physical activity, and lung health, explaining about 20% of the variance at both time-points. 
The model for FVC was adjusted for age, BMI, and physical activity, and the model for 
FEV1/FVC for age, height, lung health, and physical activity. Covariates were chosen from 
the best-fitting genetic model after comparing alternative models with different covariate 
combinations. Covariates explained 15% of the variance in FVC, and about 8% of the 
variance in FEV1/FVC. Full Cholesky models were reduced to obtain the best-fitting models, 
which were AE models for each variable. 
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The proportion of variance in FEV1 explained by each latent factor is illustrated in 
Figure 9. The genetic correlation approached unity, indicating that genetic factors affecting 
FEV1 were common at both measurements and no genetic innovations appeared. Instead, new 
environmental factors appeared at follow-up. The environmental correlation between baseline 
and follow-up was 0.69 (95% CI 0.56-0.80). The path coefficients with 95% Cls are 
illustrated in Figure 2, Study III.
 
 
Figure 9. The most parsimonious Cholesky decomposition models for FEV1, FVC, and the FEV1/FVC ratio at 
baseline in 2000 and at follow-up in 2003. The model consists of additive genetic effect A1 and nonshared 
environmental effect E1 in common for both measurement points. Each phenotype measured in 2003 has its own 
nonshared environmental effect E2. In addition, FVC measured in 2003 has its own additive genetic effect A2. The 
percentages represent the proportion of variance explained by each latent factor at each time-point and were 
derived by squaring the path coefficients x, y, and z. 
FEV1 in 2000 FEV1 in 2003 
A1 
E1 E2 
36%  
32%  
68% 
31% 
33% 
FVC in 2000 FVC in 2003 
A1 A2 
E1 E2 
41% 14% 
59 39% 
24% 
25% 
FEV1/FVC in FEV1/FVC in 
A1 
E1 E2 
16% 46%  
54% 
0.36% 
84% 
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 In the final Cholesky model for FVC (Figure 9), both new genetic and new 
environmental effects appeared at follow-up. The genetic correlation between baseline and 
follow-up was 0.80 (95% CI 0.44-1.00). Nonshared environmental effects explained 59% 
(95% CI 37-87) of the variance at baseline and 63% (95% CI 43-88) at follow-up. The 
environmental correlation between baseline and follow-up was 0.62 (95% CI 0.41-0.77). The 
path coefficients with 95% Cls are illustrated in Figure 3, Study III. 
For the FEV1/FVC ratio (Figure 9), the proportion of variance explained by genetic 
effects diminished substantially by the follow-up; however, the genetic correlation 
approached unity. Environmental correlation was 0.07 (95% CI -0.18-0.37). The path 
coefficients with 95% CIs are illustrated in Figure 4, Study III. 
5.3. Chronic bronchitis 
5.3.1. Incidence of chronic bronchitis and its association with smoking 
patterns 
The incidence of chronic bronchitis was studied in 1981 according to 1975 smoking status, 
and by excluding those with chronic bronchitis in 1975. Among the whole sample, the 
incidence was 1.7%, and among 1975 current smokers 3.0%. The risk increased linearly, 
about 1.5-fold, by each amount category of daily cigarettes among 1975 smokers (OR 1.54, 
95% CI 1.38-1.73). Despite this linear trend, when examining 1975 smokers as categories, 
only moderate (OR 3.03, 95% CI 2.26-4.06) and heavy smokers (OR 6.75, 95% CI 4.88-9.35) 
had an increased risk for incident chronic bronchitis relative to never smokers.  
Further, when examining the risk of chronic bronchitis in 1981 among the smoking 
subgroups describing the change in smoking in 1975-1981, in addition to constant moderate 
(OR 2.73, 95% CI 1.89-3.94) and heavy (OR 10.04, 95% CI 7.03-14.35) smokers, also 
smoking increasers (OR 8.10, 95% CI 5.42-12.10), decreasers (OR 3.78, 95% CI 2.16-6.62), 
and recurrent smokers (OR 2.54, 95% CI 1.31-4.93) were at increased risk for chronic 
bronchitis (see Table 1 and Figure 1, Study II). 
 To take full advantage of the repeated measurements of smoking status and chronic 
bronchitis between 1975 and 1990, we reshaped the data as panel data and constructed 
random-effects logistic regression models. Panel analyses according to smoking status 
showed that the risk of chronic bronchitis was elevated also among former smokers, as well as 
among the daily light, moderate, and heavy smokers, relative to never smokers (see Figure 
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10). When dividing former smokers into subgroups according to the duration of abstinence, 
those abstinent for over ten years had a significantly lower risk compared to those abstinent 
for less than two years. 
 
Figure 10. ORs of chronic bronchitis (1981) as well as HRs of regular anticholinergic medication (1995-2008) with 
95% CIs according to smoking categories. ORs are based on random-effects model analysis carried out on the 
panel data, and HRs are based on the Cox proportional hazards regression model for regular anticholinergic 
medication. Never smokers were used as a reference category. Continuous lines represent the results of trend 
test (thick line for regular anticholinergic medication, thin line for chronic bronchitis). 
For former smokers, p≤0.05 for chronic bronchitis and p≤0.001 for medication. For light smokers, p≤0.01 for 
chronic bronchitis and p≤0.05 for medication. Occasional smokers’ risks were nonsignificant. 
 
5.3.2. Discordant twin pair analyses 
Among twins who participated in all three surveys, there were 112 pairs discordant for 
incident chronic bronchitis in 1990. Among them, 15 twin pairs were discordant also for 
1975-1981 smoking status. In 14 pairs, the smoker had developed chronic bronchitis, whereas 
in one pair, the never-smoker was affected. With conditional logistic regression models, the 
OR for chronic bronchitis was 14.95 (95% CI 1.8-107) in smoking twins as compared with 
their never-smoking co-twins. When the analysis was restricted to DZ pairs (n=12), the OR 
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was 11 (95% CI 1.4-85). In three MZ pairs, there were no cases where the never-smoker twin 
had chronic bronchitis, and the analysis could not be conducted. 
5.4. Chronic obstructive pulmonary disease 
5.4.1. Incidence of COPD and its association with smoking patterns 
The cumulative incidence of COPD special reimbursement eligibility was 0.54% among all 
participants during a 27-year follow-up. The incidence of regular anticholinergic use was 
2.15% in the whole sample and 3.86% in ever smokers during a 13-year follow-up. Incidence 
rates among the groups describing change in smoking are presented in Figure 11. 
 
Figure 11. Cumulative incidence of COPD, measured as special reimbursement eligibility and regular 
anticholinergic use, according to smoking patterns describing change in smoking in 1975-1981. 
  
The risk of COPD, measured as regular anticholinergic medication or special 
reimbursement eligibility, was first studied according to smoking categories in 1975 and 
1981. Logistic regression models showed that the disease risk was significantly increased 
among 1975 and 1981 former, moderate, and heavy smokers relative to never smokers. 
Survival analyses, conducted separately for both outcomes, revealed that all 1981 daily 
smokers, also light smokers, had elevated risks for regular anticholinergic medication relative 
to never smokers (see Figure 10). By contrast, significantly elevated HRs for special 
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reimbursement eligibility were observed only among moderate and heavy smokers (see Study 
IV for details). 
 
Figure 12. Risk for COPD development during follow-up by smoking patterns taking into account change of 
smoking between 1975 and 1981. ***p≤0.001, **p≤0.01. For the group “moderate → light”, p-value from the 
multivariate-adjusted model ≤0.01, p-values from the age- and sex-adjusted model ≤0.05. For the group “ small 
increase” the p-value from the age- and sex-adjusted model was ≤0.001, the p-value from the multivariate-
adjusted model was ≤0.05. Heavy→light smokers, initiators, and occasional smokers not shown. 
When taking into account the change in smoking between 1975 and 1981, an 
increased risk for COPD was found for all daily smokers, other than constant light smokers. 
Results of the logistic regression models suggest that those who increased to heavy smoking, 
reduced from moderate to light smoking, increased from light to moderate smoking, or 
relapsed back to light or moderate smoking after quitting were at increased disease risk (see 
Figure 12). The main results were replicated in survival analyses, where the HR for regular 
anticholinergic medication was similar among those who reduced from moderate to light 
smoking as among smoking increasers and constant moderate smokers (see summary of the 
results of survival analyses in Table 3). For details, see Figure 2 and Table III in Study IV.  
 The risk of having ever used anticholinergic medication was further studied among 
subgroups describing change in smoking. Former, constant light, moderate, and constant 
heavy smokers as well as smoking increasers had purchased combination preparations of 
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anticholinergics and beta agonists significantly more often than never smokers. For pure 
anticholinergics, elevated risks were observed for the same smoking groups, excluding 
constant light smokers. A summary of the risks of inhaled medication use according to change 
in smoking status is presented in Table 3. Detailed results are reported in Study IV. 
Table 3. Summary of the results of COPD risk according to change in smoking patterns. Results are based on 
logistic regression analyses of anticholinergic medication and survival analyses of anticholinergic medication and 
special reimbursement eligibilities. Categories describing change in smoking in 1975-1981 are presented on the 
left. Occasional smokers, initiators, heavy→light smokers not shown. ↑ significantly increased risk (p<0.05), ↔ 
nonsignificant risk relative to constant never smokers. Constant light smokers and moderate→light smokers were 
omitted from the survival analyses of special reimbursements because there were no affected cases among 
these groups. 
 
Combination 
preparations 
(logistic 
regression) 
Pure 
anticholinergics 
(logistic 
regression) 
Regular 
anticholinergic 
medication (survival 
analysis) 
Special reimbursement 
eligibility (survival 
analysis) 
Former smokers ↑ ↑ ↑ ↔ 
Constant light 
smokers 
↑ ↔ ↔ Omitted 
Moderate→light ↔ ↔ ↑ Omitted 
Small increase ↔ ↔ ↔ ↑ 
Constant moderate ↑ ↑ ↑ ↑ 
Constant heavy ↑ ↑ ↑ ↑ 
Increasers ↑ ↑ ↑ ↑ 
 
5.4.2. Discordant twin pair analyses 
Conditional logistic regression analyses were conducted for twin pairs discordant for COPD. 
The risk estimates related to smoking patterns were similar to those seen when analyzing the 
data as individuals; risk of COPD was significantly elevated among smoking increasers (OR 
6.15, p=0.004) and moderate (OR 8.98, p≤0.001) or heavy smokers (OR 10.2, p≤0.001). 
When the analyses were conducted separately for MZ and DZ pairs, the results in DZ pairs 
remained significant (moderate smokers: OR 10.8, p≤0.001; increasers: OR 7.71, p=0.007; 
heavy smokers: OR 9.36, p=0.004). Although not reaching statistical significance, the risk 
estimates remained high also for MZ pairs; the ORs were 7.69 for moderate and 24.6 for 
heavy smokers, whereas no COPD cases among increasers were observed. 
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6. Discussion 
6.1. Summary of aims and results 
The first aim was to study the prevalence and consistency of different smoking patterns in a 
Finnish population by focusing on the subgroup of daily light smokers, and to examine the 
characteristics of Finnish light smokers. In a representative Finnish population sample, daily 
light smokers were found to more likely be females, well-educated, physically active, and 
exhibiting other healthy lifestyle characteristics than heavy smokers. Daily light smoking was 
a temporary pattern for most individuals, whereas at the population level, the proportion of 
light smokers remained constant. 
 The second aim was to explore the heritability of lung function by using spirometry 
results of never-smoking twins from two time-points. Among elderly never-smoking females, 
genetic effects explained about one-third of the observed variance in FEV1 and FCV, and 16-
46% of the variance in the FEV1/FVC ratio. The genes influencing FEV1 and FEV1/FVC 
were the same at different time-points, whereas for FVC, new genes explaining 14% of the 
variance were observed at follow-up. Environmental factors other than smoking were found 
to be important determinants of lung function. 
 The third aim was to estimate the incidence and risk of chronic bronchitis according to 
various smoking patterns by taking into account changes in smoking over time. The risk of 
incident chronic bronchitis was increased among constant heavy and moderate smokers, 
among those who increased or decreased their smoking during follow-up, and among those 
who relapsed back to regular smoking after quitting. Further analyses with panel data showed 
that the risk of chronic bronchitis was also increased among light and former smokers when 
the change in smoking status was not taken into account. 
 The fourth aim was to estimate the incidence and risk of COPD over a 27-year follow-
up according to changes in smoking patterns that occurred before the beginning of the follow-
up. Constant heavy and moderate smokers, smoking increasers, those who decreased from 
moderate to light smoking, or those who relapsed back to moderate or light smoking after 
quitting were at increased risk for COPD. Light smoking measured at one time-point was also 
associated with an increased COPD risk, and constant light smoking was associated with an 
increased use of anticholinergic medication.  
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6.2. Main results and comparison with previous studies  
6.2.1. Light smoking 
By comparing the characteristics of light smokers with those of heavy smokers, the likelihood 
of light smoking was found to be increased among women, subjects with higher education, 
physically active subjects, tea drinkers, and subjects reporting less stress and older age at 
smoking initiation. Use of other tobacco products, heavy alcohol and coffee consumption, and 
being married or living with a partner, by contrast, were more likely present in heavy 
smokers. Among current smokers, the proportion of light smokers remained constantly at 8%, 
although on an individual level this pattern was rarely consistent. Baseline age of 26-30 years 
or over 40 years predicted continuous light smoking versus quitting. Change in marital status 
predicted change in light smoking pattern, and higher education predicted continuous light 
smoking versus increasing smoking. Baseline heavy alcohol use predicted increasing smoking 
versus continuous light smoking. 
The observed prevalence of light smoking is in line with international studies from the 
1990s (Rosengren, Wilhelmsen & Wedel 1992, Owen et al. 1995, Zhu et al. 2003). More 
recent studies have, however, shown that the proportion of light smokers is increasing in 
countries with decreasing overall smoking prevalence (Pierce, White & Messer 2009, 
Shiffman 2009). In 2009, the proportion of light smokers among American smokers was 
estimated to be 15% (Shiffman 2009). One limitation of this study is that the screening of 
smoking patterns took place over 30 years ago, and the results are not applicable to the 21st 
century Finnish population. The subgroup of light smokers in the population may have 
changed after the participants attended the study. Interestingly, the proportion of occasional 
smokers in the Finnish population has not changed significantly since the 1970s (Helakorpi et 
al. 1999, Luoto, Uutela & Puska 2000, Helakorpi, Laitalainen & Uutela 2010), although the 
prevalence of occasional smoking is increasing in many other countries (Shiffman 2009). 
Light smokers exhibited healthier lifestyle and mental health characteristics than 
heavy smokers. Those who increased from light to heavy smoking were already at baseline 
more stressed and dissatisfied than other light smokers. The associations between smoking 
and alcohol and coffee consumption are well-known (Carmody et al. 1985, John et al. 2003), 
and heavy smoking has previously also been shown to be associated with stress (Nielsen et al. 
2008). Higher education and physical activity among light smokers suggest that they are more 
aware of the health effects of smoking than heavy smokers and possibly aim at harm 
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reduction. The higher prevalence of light smoking among unmarried subjects has also been 
previously demonstrated (Hyland et al. 2005). As quitting rates are higher among married and 
better-educated subjects (Broms et al. 2004), it seems logical that moving in with a partner 
predicted change in light smoking also in this sample. In conclusion, earlier research on light 
smokers and their characteristics is in line with the results of Study I (Okuyemi et al. 2002, 
Hyland et al. 2005, Pierce, White & Messer 2009). The results support the view that the 
population of light smokers in Finland is very similar to that in other Western countries.  
Reporting inhalation was more common among heavy smokers than light smokers. 
Although inhalation was crudely dichotomized in the questionnaire, and no biochemical 
validation of nicotine intake was used, this result suggests that light smokers are not be as 
nicotine-dependent as heavy smokers. Earlier studies, particularly by Dr. Saul Shiffman, have 
examined and discussed this issue extensively (Shiffman & Paty 2006).  
6.2.2. Lung function 
Heritability of lung function was estimated in a sample of elderly never-smoking women. 
Previous studies using twin modeling have reported slightly higher heritability estimates 
(McClearn et al. 1994, Palmer et al. 2001, Hallberg et al. 2010). The heritability of 
FEV1/FVC was found to be 46% at baseline, which is in line with previously reported (Wilk 
et al. 2000). At follow-up, however, the estimated heritability of FEV1/FVC was only 16%. 
This marked change during only a three-year follow-up may be explained by a concomitant 
increase in time-specific environmental effects, such as disease processes or accidents.  
 Results of the lung function heritability show that environmental factors other than 
smoking are important determinants of pulmonary function. In this study, all environmental 
effects were found to be nonshared, whereas earlier studies have reported that shared 
environmental effects also explain a small proportion of the variance in FEV1 and FVC 
(Palmer et al. 2001, Hallberg et al. 2010). The environmental factors seem to be time-specific; 
at follow-up, more than half of the environmental factors loading on FEV1 and FVC and all 
of those loading on FEV1/FVC were novel. Examples of environmental effects affecting lung 
function at both time-points are socioeconomic status, occupational exposure, and passive 
smoking. Disease processes, accidents, and life events, in turn, are examples of specific 
environmental factors during the follow-up. Disease processes affect nutritional status, 
physical activity level, and muscle strength, all of which have an impact on respiratory 
function. Life events, such as losses and depression, may also affect functional capacity. 
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Sarcopenia inevitably occurs in old people, decreasing the capacity of the thorax. The results 
emphasize the importance of physical activity, nutrition, rehabilitation, and interventions also 
in older age since environmental factors other than smoking can substantially contribute to 
lung function. Poor lung function, in turn, increases the risk for cardiovascular diseases, 
metabolic syndrome, and overall mortality (Sin, Wu & Man 2005, Kohansal et al. 2009, 
Steele et al. 2009). 
 Additive genetic effects explained one-third of the variation in FEV1 and FVC at both 
baseline and follow-up. The genetic influences loading on FEV1 and FVC have also been 
earlier reported to consist of additive genetic effects (Palmer et al. 2001, Zhai et al. 2007, 
Hallberg et al. 2010). For FEV1/FVC, the heritability estimate decreased substantially during 
follow-up. For FVC at follow-up, new genetic effects emerged and explained 14% of the 
variance, whereas for FEV1 and FEV1/FVC the genetic effects remained the same as at 
baseline. The results are in line with the current view that multiple genes contribute to lung 
function. Environmental effects seem to easily displace the influence of genes on FEV1/FVC 
since the observed variance in FEV1/FVC at follow-up was explained to a great extent by 
environmental factors. 
The decomposition of observed lung function variance into time-specific genetic and 
environmental effects has not been performed earlier. Longitudinal results on lung function 
heritability exist only for the decline rates of FEV1, FVC, and their ratio (Gottlieb et al. 
2001). One previous study estimated the heritability of FEV1 among never smokers; it was 
found to be about half of that observed in current smokers (Zhai et al. 2007). Studies reporting 
higher heritability estimates for FEV1 and FVC or VC have included both smokers and 
nonsmokers, and results have been based on single spirometry measurements (Palmer et al. 
2001, Hallberg et al. 2010).   
One limitation of this study is that the results are applicable only to elderly never-
smoking Caucasian females; thus, no conclusions can be made regarding men or young 
women. However, as the prevalence of ever-smoking is much higher in elderly men than in 
women, excluding the effect of smoking would be more complicated. Few studies have 
examined the gender differences of lung function heritability, and their results are 
controversial (McClearn et al. 1994, Hallberg et al. 2010). No gender differences have been 
reported in GWAs investigating variants associated with lung function. 
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6.2.3. Chronic bronchitis 
This study revealed that the risk of chronic bronchitis increases almost linearly with the daily 
amount of cigarettes. The six-year incidence of chronic bronchitis varied between 1.9% and 
5.2% among smoker groups with elevated risks. Reduction from moderate to light smoking 
was associated with an elevated disease risk, showing that reduction does not protect from 
chronic bronchitis. By contrast, no elevated risk of chronic bronchitis was observed in 
quitters. The results support the view that smoking cessation may improve pulmonary 
symptoms, whereas smoking reduction does not offer any harm reduction. However, panel 
analyses studying the risk of chronic bronchitis according to smoking status found increased 
disease risks also in light and former smokers. This finding may reflect increased symptoms 
among those former smokers who had been abstinent for only a short period or who relapsed 
during the follow-up. Similarly, those light smokers who had previously smoked more or 
increased their smoking during follow-up were likely to exhibit an increased chronic 
bronchitis risk. 
Earlier incidence studies on chronic bronchitis according to different smoking patterns 
are few. A Finnish cohort study found the lifetime incidence of chronic bronchitis to be 42% 
in smokers (Pelkonen et al. 2006). Increased prevalence rates of chronic bronchitis have been 
previously reported among former smokers, and the risk has been estimated to approach that 
of never smokers in five years (Brown et al. 1991, Troisi et al. 1995, Willemse et al. 2004). 
This is in line with our finding that former smokers abstinent for over ten years exhibited a 
lower risk for chronic bronchitis than those abstinent for less than two years.  
Few studies have examined the association between light smoking and chronic 
bronchitis. A Finnish study found no increased risk associated with smoking <5 CPD 
(Pallasaho et al. 1999), whereas other studies have reported that smoking <10 CPD increases 
the risk of different respiratory symptoms (Amigo et al. 2006, Vianna et al. 2008). Substantial 
reductions in CPD have been described to decrease other respiratory symptoms (Hughes & 
Carpenter 2006, Pisinger & Godtfredsen 2007), not, however, chronic bronchitis (Simmons et 
al. 2005, Bohadana et al. 2006). This finding was confirmed here; the risk of chronic 
bronchitis among smoking reducers was at a similar level as that among daily moderate 
smokers. 
This study supports the view that smoking reduction does not decrease the risk of 
chronic bronchitis, whereas permanently quitting smoking does. After quitting, the risk seems 
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to decline and is finally no longer significant relative to never smokers. Although no 
increased risk was observed for constant light smokers, a novel finding in this study was that 
light smoking measured at one time-point is associated with chronic bronchitis. The mean age 
of light smokers was 40.5 years in 1981, when chronic bronchitis was studied. Because 
chronic bronchitis morbidity correlates with pack-year exposure, the observed risk estimate 
for constant light smokers was possibly insignificant because their smoking history was rather 
short in 1981. With longer follow-ups, increased risks may be found also for constant light 
smokers. 
6.2.4. COPD 
This study demonstrated that moderate and heavy smokers, former smokers, those who 
reduced from moderate to light smoking, smokers relapsing to light / moderate smoking after 
quitting, and light smokers increasing their consumption to moderate smoking were at 
increased risk for COPD development. Light smoking, measured cross-sectionally in 1981, 
was also associated with COPD development, whereas constant light smoking over a six-year 
follow-up was associated with an increased risk for anticholinergic medication. The risk for 
COPD has not been estimated previously by taking into account changes that occur in 
smoking patterns longitudinally. The effects of light smoking and smoking reduction on 
respiratory health are only partially understood, and studies on their association with COPD 
are few. The novel findings of this study suggest that the risk of COPD is not altered by 
smoking reduction and that light smoking also increases the risk of COPD. Constant light 
smoking is likely to increase respiratory symptoms and pulmonary dysfunction since it was 
found to be associated with increased use of anticholinergic medication, although this use was 
not regular.  
Successive measurements of smoking and the long follow-up of COPD development, 
based on national registry data of a large population sample, are factors increasing the 
reliability of these results. The incidence of COPD in this study was, however, much smaller 
than previously reported (Huhti & Ikkala 1980, Johannessen et al. 2005, de Marco et al. 
2007). This is probably due to the disease definition used here: only symptomatic COPD 
patients are likely to end up using regular medication. Moreover, special reimbursement 
eligibility is given only to subjects suffering from severe disease. 
 Cross-sectional light smoking has been previously reported to be associated with mild 
COPD, defined by GOLD criteria, among subjects aged over 45 years (Lundbäck et al. 2003). 
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However, because the GOLD criteria may overdiagnose COPD in the elderly, spirometry-
defined mild COPD may also reflect age-related decline in lung function. This study revealed 
that among the Finnish adult population, constant light smokers purchase combination 
preparations of ipratropium and beta2 agonist significantly more often than never smokers. 
Medication use reflects increased pulmonary symptoms. Moreover, these subjects have 
sought a doctor’s appointment since all medication purchases in Finland require a doctor’s 
prescription. This the first time constant light smoking has been found to be associated with a 
COPD-related outcome. The results show that all levels of daily smoking may damage the 
lungs. Environmental factors were found in Study III to be important determinants of lung 
function, and all regular exposure to tobacco smoke appears to have detrimental effects on the 
lungs.  
As many as 17% of the observed COPD cases were never smokers, although only 
0.9% of all never smokers were affected. One possible explanation for this is that some of 
these 1975-1981 never smokers had taken up smoking during the follow-up. However, among 
those who attended again in 1990 (42%), all except one reported still being a never smoker. 
COPD in never smokers may be explained by other known risk factors, such as occupational 
exposure and passive smoking. Unfortunately, these factors were not assessed here and their 
relationship to COPD falls outside the scope of this thesis. 
 The mean age of participants was 40.2 years in 1981 and 67.2 years at the end of the 
follow-up in 2008. The 27-year follow-up of COPD development may have been too short to 
reveal all disease cases in the sample, as COPD incidence continues and cases accumulate 
beyond the age of 70 years (Pelkonen et al. 2006). Among constant light smokers and those 
who reduced from moderate to light smoking, no cases with a special reimbursement 
eligibility for COPD were observed. The average age of those who were light smokers in 
1981 was only 61.5 years at the end of follow-up, thus, many of them may still develop 
COPD later in life. It is also possible that some study subjects suffered from mild, 
asymptomatic COPD during the follow-up and went undetected. 
6.3. Methodological considerations 
6.3.1. Representativeness of the study sample 
This thesis aimed to assess different smoking patterns and their effects on pulmonary health at 
a population level. Participants of the Older Finnish Twin Cohort, a population-based study 
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with high response rates (Kaprio & Koskenvuo 2002), formed an excellent and representative 
sample for this purpose. The study sample of this thesis was composed mainly of those 
subjects who attended the follow-up in 1975 and again in 1981. In 1990, the invitation to 
participate was sent only to pairs born in 1930-1957 to avoid bias caused by increased 
morbidity in the older age group. A study based on the same cohort found that smoking and 
poor life satisfaction predicted nonparticipation in 1990 (Korhonen et al. 2007). If smokers 
dropped out more often than nonsmokers also from the 1975 and 1981 surveys, the 
prevalence of smoking may have been slightly underestimated in this study. 
Heritability of lung function was investigated in the FITSA subsample, which, by 
contrast, is not as representative as the initial cohort. Walking and traveling ability were 
among the inclusion criteria, resulting in a small sample of participants who were probably 
healthier than women of the same age in the general population. Ever-smoking prevalence 
among the initial FITSA sample was 13.6%, which is low compared with women aged 65-74 
years nationally (20.1% in 2001). The study subjects were also physically more active and 
their self-perceived health was better than same-aged women in the population (Sulander et 
al. 2001). At baseline, 62% of FITSA participants reported intermediate and 34% high 
physical activity, and at follow-up, these proportions were 60% and 30%. The proportion of 
participants suffering from chronic diseases, such as coronary heart disease, hypertension, and 
type 2 diabetes, was also lower than in the national sample (Sulander et al. 2001). The drop-
out rate was moderate when taking into account the advanced age of participants; of the never 
smokers who attended spirometry, 74% participated in all measures again at follow-up. The 
baseline lung function among subjects who dropped out from the follow-up was, however, 
poorer than average, so nonparticipation at follow-up may have affected the results. 
6.3.2. Measurement of smoking  
Formation of smoking categories was based on self-reported smoking patterns, and no 
biochemical validation was used. About 75% of nicotine is metabolized to cotinine, which is 
regarded as the best biomarker for detecting exposure to tobacco smoke (Vasankari et al. 
2011). The proportion of smokers in the twin cohort (32% in 1975, 28% in 1981) was, 
however, very similar to that in the Finnish general population in the 1970s and 1980s 
(Helakorpi et al. 1999), suggesting that participants reported their tobacco consumption 
honestly. Alternatively, if reporting bias existed, it was similar to that in the population-based 
health behavior surveys conducted in Finland.  
70 
 
 Earlier validation studies in Finland have shown that smokers report their smoking 
status accurately; among self-reported never smokers, only 2.0-2.7% have had serum cotinine 
levels suggestive of smoking (Laatikainen, Vartiainen & Puska 1999, Vartiainen et al. 2002). 
However, a recent study using biochemical verification of smoking found that 7% of self-
reported never smokers were actually smokers. In that study, the serum cotinine level was 
actually a better predictor of obstruction than self-reported smoking status (Vasankari et al. 
2011). Biochemical verification of smoking would certainly have been advantageous also in 
this study. However, the twins represent the general population and results on cotinine values 
in Finnish samples are applicable to the twin cohort participants as well.  
In this study, further smoking subgroups were formed to reflect the change in smoking 
patterns over a six-year period. Many participants had the same smoking status in both years, 
some quit during follow-up, and some increased their consumption, while the proportions of 
smoking decreasers and low-rate smokers were smaller (see Figure 3, Methods). The mean 
age of participants was 40.2 (SD 13.4) years in 1981. As smoking patterns acquired in middle 
age are usually stable (Culverhouse et al. 2005), smoking patterns in 1981 were likely to 
describe subjects' exposure over a longer time span. Accordingly, these smoking subgroups 
describe the cumulative exposure more precisely than cross-sectionally measured smoking. 
This is an important strength of this study, where the aim was to investigate long-term 
exposure and how it predicts several lung health outcomes. 
The lifetime number of pack-years is the most significant risk factor for COPD 
(Burrows et al. 1977, Rennard & Vestbo 2006). Pack-year exposure based on a single report 
of cigarette consumption is, however, often unreliable. The daily number of cigarettes is a 
reliable measure, and when analyzed longitudinally, it reflects the changes that occur in 
tobacco exposure. In Studies II and IV, the models examining chronic bronchitis and COPD 
were adjusted for age as well as for pack-years, unless the correlation between pack-years and 
smoking categories was ≥0.6.  
In the FITSA study, history of ever-smoking was based on self-reports. The proportion 
of never smokers was 86% among the initial study population, which is higher than in a 
national sample of elderly women (Sulander et al. 2001). The possibility that some subjects 
might have falsely classified themselves as never smokers cannot be excluded. This concerns 
especially those participants who smoked decades ago and only for a short period. 
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6.3.3. Measurement of outcomes 
6.3.3.1. Lung function 
Spirometry is one of the most accurate means of measuring lung function, and it was 
performed in the FITSA study according to international guidelines. Instructions and 
encouragement were given by professional technicians and the maneuvers were practiced 
until at least two were acceptable. The spirometer was calibrated daily with a three-liter pump 
and was accurate to within 1%. The spirometry values are likely reliable and equivalent to 
subjects’ true pulmonary function. 
 The obtained spirometry results cannot, however, be generalized without qualification 
to elderly females. First, the reported results were based on measurements among never 
smokers only, and second, the study subjects were probably healthier than women of their age 
in the general population. However, the sample was derived from the relatively isolated 
Finnish population. An isolated population exhibits less genetic variability and shares a more 
uniform environment than outbred populations (Peltonen, Palotie & Lange 2000). This can be 
considered an advantage, increasing the representativeness of the study sample. 
 The mean FEV1 and FVC levels were higher than the mean expected FEV1 and FVC 
levels, which is in line with the small prevalence of pulmonary diseases and high physical 
activity among participants. However, the mean FEV1/FVC ratio was lower than the mean 
age- and height-correlated reference value, which supports the view that in elderly subjects 
FEV1/FVC<70% may be a normal phenomenon (Kerstjens et al. 1997, Medbo & Melbye 
2007). However, as the Finnish reference values can be reliably applied only to subjects aged 
under 65 years (Sovijärvi et al. 2006), the estimation of expected lung function values among 
FITSA participants may be inaccurate.  
 Although the annual decline in FEV1/FVC speeds up in subjects aged over 70 years 
(Kerstjens et al. 1997), in the study sample the mean FEV1/FVC was greater at follow-up 
(77.4%) than at baseline (74.4%). However, as the values of FEV1 and FVC were both 
smaller at follow-up than at baseline, the spirometry measures are likely reliable and the 
observed increase in mean FEV1/FVC is a result of a higher decrease in mean FVC relative to 
FEV1. The mean lung function values were slightly greater among MZ twins than among DZ 
twins, except the FEV1/FVC ratio at baseline, which was higher among DZ twins. This may 
be related to the fact that, on average, MZ twins live longer than DZ twins (Zaretsky 2003). 
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Comparison of the genetic models to the saturated models, however, showed that the means 
and variances in spirometry values did not significantly differ by zygosity. 
Twins are born smaller and at earlier gestational age than singletons, and in some 
populations, young adult twins have been reported to remain shorter and lighter than 
singletons (Pietiläinen et al. 1999, Silventoinen et al. 2008). As lung development lasts until 
young adulthood, smaller body size in twins may also result in smaller maximum lung 
capacity. Female MZ twins aged 45-65 years have also been reported to be slightly lighter 
than DZ twins and singletons (Andrew et al. 2001). The genetic models used in Study III were 
all adjusted for BMI or height, however, the average body size of the twin sample was not 
compared with that of elderly females in the general population. 
Among strengths of the study design were exclusion of smoking effect and repeated 
spirometry measures. Controlling for the smoking-gene interaction was possible by including 
only never smokers in the study. Repeated lung function measurements allowed estimation of 
the changes in the proportions of genetic and environmental effects over time and 
examination of the correlations between baseline and follow-up estimates.  
6.3.3.2. Chronic bronchitis 
The diagnosis of chronic bronchitis is based on self-reported symptoms of long-standing 
cough and sputum production. The MRC question series is the appropriate way to define 
chronic bronchitis (British Medical Research Council 1960, Bobadilla et al. 2002) and was 
used also in the twin cohort questionnaires to identify subjects with chronic bronchitis.  
 The diagnosis of chronic bronchitis is based on self-reported symptoms, and no 
common objective way exists to measure the disorder. Accordingly, false-positive diagnoses 
may have occurred in, for example, cases of bronchiectasis, long-standing sinusitis, or 
untreated asthma (Bobadilla et al. 2002), where chronic cough and sputum production are 
sometimes present. In the twin cohort questionnaire, asthma was screened as a physician-
made diagnosis, whereas bronchiectasis and sinusitis were not screened. The proportion of 
subjects with asthma among those suffering from chronic bronchitis was 6% in 1975 and 15% 
in 1981. The prevalence of bronchiectasis started to decline in Finland in the 1960s, and has 
been a rare condition since the 1980s (Säynäjäkangas et al. 1998). 
 A Swedish study interviewed and performed spirometry on subjects who had first 
completed questionnaires about respiratory symptoms. Of subjects reporting chronic 
productive cough, 17% actually had asthma, and elderly smokers were likely to underreport 
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their symptoms of chronic bronchitis on the questionnaire (Lundbäck et al. 1993). Thus, the 
high proportion of asthmatics in the chronic bronchitis group in 1981 may reflect increased 
susceptibility to cigarette smoke or false-positive diagnoses of chronic bronchitis among 
asthmatics. A recent Finnish study conducted among asymptomatic smokers revealed that 
62% actually suffered from chronic cough or sputum production (Toljamo et al. 2010). As 
shown by these studies, smokers are not always aware of their respiratory symptoms or may 
deny them. Thus, underestimation of chronic bronchitis due to underreporting cannot be ruled 
out in Study II.  
6.3.3.3. COPD 
COPD was defined in Study IV as regular anticholinergic use (at least two purchases of 
anticholinergic inhalation preparations from the pharmacy at a maximum of 99-day intervals) 
or a diagnosis of COPD, chronic bronchitis, or emphysema entitling to special reimbursement 
eligibility. The anticholinergic medication criterion revealed 416 COPD cases, whereas 112 
subjects were given a special reimbursement eligibility due to COPD, chronic bronchitis, or 
emphysema. 
 The main limitation of the COPD definition used in Study IV is that mild COPD and 
asymptomatic cases were likely excluded. First, the current care guidelines recommend 
medication use only for symptomatic COPD patients, and those with mild symptoms are 
sometimes treated with only beta2 agonists. Second, anticholinergic medication, as most other 
medications in Finland, cannot be purchased from a pharmacy without a physician’s 
prescription. As anticholinergic compounds are generally used to treat no conditions other 
than COPD, a medical examination and suspicion or diagnosis of COPD precede regular 
anticholinergic use. Accordingly, this is not likely to occur unless subjects become concerned 
about their pulmonary symptoms – and COPD patients easily become accustomed to their 
early symptoms (Toljamo et al. 2010). Third, special reimbursement eligibility for COPD 
medication is given only to subjects suffering from severe COPD as defined in lung function 
testing. Taking into account these limitations, the disease definition likely did miss some 
cases and falsely classified some affected subjects as healthy. The possibility of false-positive 
diagnoses, by contrast, is low. 
 Medications used during hospitalization periods or purchased abroad or in the 
pharmacy without presenting a health insurance card are not tracked in the SII. Accordingly, 
the disease definition used in Study IV may have missed such medication use. However, it is 
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unlikely that COPD patients would be admitted to hospital, treated there, but not continue 
anticholinergic medication afterwards. It is also uncommon not to present the health insurance 
card, which subsidizes 42% of the medication price. However, subjects with a special 
reimbursement eligibility due to another pulmonary disease, such as asthma or cystic fibrosis, 
who later developed COPD were more likely missed. The special reimbursement criterion 
may not have detected such persons because they do not need another certificate in order to 
receive a special reimbursement for pulmonary medications. In the twin cohort data, 19% of 
defined COPD cases had a special reimbursement eligibility for asthma. Indeed, asthma may 
evolve into COPD, and the coexistence of asthma and COPD, where patients have features of 
both, is common among elderly subjects (Gibson & Simpson 2009). One-fifth of elderly 
Finnish asthmatics use anticholinergics, suggesting that they also express features typical to 
COPD (Ikäheimo et al. 2005). 
Among strengths of this follow-up of COPD development is the use of national 
registries, where drop-outs occur only if people die or move abroad. A spirometry follow-up 
would have resulted in a more accurate diagnosis; however, more drop-outs, especially among 
elderly subjects, would have occurred. Anticholinergic purchases registered by the SII have 
been used also previously to define COPD (Tynkkynen et al. 2009). Medication purchases are 
well covered in the SII because reimbursement for medication price is obtained when the 
health insurance card is presented at the pharmacy, and the purchase is then recorded. Regular 
anticholinergic medication, recommended by the national guidelines for COPD, is rarely used 
for other conditions. In Finland, physicians are educated in five medical schools with similar 
methods, and national treatment recommendations are carefully followed (Jousilahti et al. 
2007).  
6.3.4. Confounders 
Most variables, e.g. alcohol use and physical activity, were screened with detailed, sometimes 
multiple questions, making the reported characteristics reliable (see Methods for detailed 
description). More unreliable variables include inhalation pattern, which was dichotomized as 
'yes' or 'no'. However, only 6-7% of current smokers reported not inhaling in 1975 and 1981. 
Lifetime pipe or cigar smoking was defined as having smoked at least 3-5 packages of pipe 
tobacco or at least 50 cigars / 75 cigarillos. In 1975, 18% of the study population reported 
having ever smoked pipe or cigars. However, only 11.5% reported having smoked pipe or 
cigars regularly. These variables were used only in Study I when examining the characteristics 
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of light and heavy smokers. Because no data were available on daily amount of pipes and 
cigars smoked, the exposure could not be evaluated similarly as smoking in Studies II and IV. 
Smokeless tobacco use was not measured; however, its use in Finland during the 1970s and 
1980s was rare (IARC Working Group on the Evaluation of Carcinogenic Risks to,Humans 
2007). 
Asthma and allergic rhinitis were screened by asking whether subjects had a diagnosis 
set by a physician. This may have resulted in underestimation of asthma and allergic rhinitis 
since not all affected subjects are diagnosed. However, accurate diagnosis of asthma cannot be 
performed in a questionnaire study; instead, this would require lung function measurements.  
 In Study III, participants’ characteristics were measured in 2000 and again in 2003. 
Physical activity and disease status were self-reported. Physical activity and morbidity were 
assessed with multiple specific questions. Unfortunately, no post-bronchodilator spirometry 
was performed, which would have resulted in more accurate asthma diagnoses compared with 
self-reports. Possibly, elderly subjects may have overestimated their activity and capacity if 
they recently had experienced limitations in their performances. Difficulties in accepting 
one’s reduced capacity may cause overestimation of self-reported physical activity and 
underreporting of morbidity.  
Passive smoking and occupational exposure were not assessed in the twin cohort 
questionnaires or in the FITSA study. However, they may be important environmental factors 
affecting lung function in never smokers. In Western countries, smoking is the main factor 
causing chronic bronchitis and COPD (Mannino & Buist 2007). Occupational exposure has, 
however, been estimated to account for 15% of the burden of COPD in Western countries 
(Balmes et al. 2003, Salvi & Barnes 2009), and similar rates have been reported in Finland 
(Nurminen & Karjalainen 2001). In addition, passive smoking increases the susceptibility for 
chronic bronchitis and COPD (Radon et al. 2002, Mannino & Buist 2007, Yin et al. 2007). 
One limitation of this study is that passive smoking and occupational exposure were not taken 
into account. They might have explained part of the disease burden among never smokers. In 
genetic modeling, passive smoking and occupational exposure were included as unique 
environmental effects, but their proportional impact among other environmental factors is 
impossible to distinguish. 
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6.3.5. Statistical analyses 
6.3.5.1. Random-effects models 
In Study II, after reshaping the data into longitudinal panel data, increased risks of chronic 
bronchitis were found for former and light smokers with a random-effects regression model. 
The random-effects model made use of all information available on smoking patterns and 
analyzed data from all three measurement points simultaneously. As random-effects model 
assumes that repeated measurements are independent of each other and that heterogeneity 
between subjects is partially explained by unobservable effects (Diggle et al. 2002). Further, 
random-effects models can take into account data on subjects who later drop-out from the 
study (Hedeker & Gibbons 1997). The initial logistic regression models analyzing smoking 
status in 1975 and incidence of chronic bronchitis in 1981 found no significantly elevated 
risks for former and light smokers, probably because of the smaller number of observations 
compared with the random-effects model. However, in the pooled panel data, it could not be 
ascertained whether smoking patterns in a certain year preceded subsequent chronic 
bronchitis. Nor could the changes in smoking patterns be taken into account in this data. 
However, the other statistical analyses used in Study II established the causal relationship 
between smoking and COPD, and also evaluated the changes in smoking patterns. 
6.3.5.2. Discordant twin pair analyses 
Discordant twin pair analyses were conducted in Studies II and IV. In Study II, 112 pairs were 
discordant for chronic bronchitis, whereas 15 pairs (12 DZ, 3 MZ) were discordant also for 
smoking. The analysis conducted among all pairs could be repeated separately only for DZ 
twins, because among the three MZ pairs, there were no pairs in which the never-smoker co-
twin was affected. Among DZ twins, the association between smoking and chronic bronchitis 
remained significant, and it is likely that with a larger sample, a similar association would be 
observed also in MZ twins. In Study IV, the sample of the discordant twin pair analyses was 
probably again too small. There, 325 pairs discordant for COPD were observed, and the 
association with smoking was analyzed among MZ (n=81) and DZ (n=213) pairs separately. 
The risk estimates associated with smoking were significant only among DZ pairs; those in 
MZ twins were high, albeit nonsignificant. According to these results, the possibility that 
some of the associations between smoking and COPD are explained by genetic factors cannot 
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be ruled out. It is more likely, however, that nonsignificance among MZ pairs was obtained 
because of the relatively small sample size. 
6.3.5.3. Genetic modeling 
Heritability of lung function was studied among never-smoking elderly females. The sample 
was rather small and, unfortunately, some drop-outs occurred at follow-up. The drop-out rate 
was similar in MZ and DZ twins. Despite the limitations, the sample was well suited for 
quantitative genetic modeling. At the time of baseline measurements, the zygosity of the 
twins was ascertained from blood sample DNA, and acceptable spirometry was obtained for 
157 MZ and 182 DZ twins. Similar measurements were performed at three-year intervals, 
enabling the analysis of the data with a Cholesky decomposition model. A potential source of 
bias is the baseline requirement that both twins had to participate. It may have resulted in 
exclusion of pairs in which one sister was unhealthy or unable to travel, and consequently, the 
twin similarity may have been overestimated. 
In genetic modeling, correct estimation of the genetic and environmental components 
affecting a phenotype requires fulfillment of certain assumptions. These include equal 
environments for MZ and DZ twins and the absence of GxE interaction, GE correlation, and 
assortative mating (Posthuma et al. 2003).  
Equal shared and unique environments assumes that no differences exist between the 
means within MZ and DZ twin pairs and that an equal degree of environmental variation is 
present within them. Equality of environmental effects was tested by comparing genetic 
models to saturated ones; as the means and variances of lung function did not significantly 
differ by zygosity, this assumption appears tenable. Assortative mating, meaning that 
individuals choose spouses that resemble themselves, is known to occur for many traits, e.g. 
intelligence (Posthuma et al. 2003). Assortative mating tends to increase the similarity of DZ 
twins relative to MZ twins. If the parents of the twins had similar lung function, then the 
spirometry values of the twins would be more similar than expected due to higher genotypic 
resemblance. Although spouse correlations for current smoking are high (Boomsma et al. 
1994), assortative mating regarding smoking is unlikely to have affected the study subjects; at 
the time they were born, smoking among women in Finland was rare (Helakorpi et al. 2004). 
Instead, assortative mating based on social homogamy (Evans, Gillespie & Martin 2002), e.g. 
among farmers, is possible, but does not result in genotypically more similar lung function in 
offspring. 
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As suggested by earlier studies (Silverman et al. 1998, Wilk et al. 2000, Zeller et al. 
2010), an important source of GxE interaction is that between smoking and genes determining 
lung function. This was taken into account by excluding ever smokers from the study. 
However, other factors, such as occupational exposure, have also been shown to modify the 
genetic expression of lung function (Pacheco et al. 2010), and these were not taken into 
account in Study III. GE correlation occurs, for instance, when parents transmit both genes 
and environment affecting certain phenotype, or when subjects actively select environments 
correlating with their genotype. GE correlation may be active, passive, or reactive, and it is 
usually difficult to measure. GE correlation increases the phenotypic variance at the 
population level (Posthuma et al. 2003). For example, children with genetically determined 
poor lung function may actively choose not to practice sports, which may impair their 
achievement of maximal lung capacity. 
In addition to dominant and additive genetic effects and the interaction between genes 
and the environment, there is also an interaction between genes, i.e. epistatic effects between 
different loci. In classical twin modeling, the epistatic effects are modeled as part of A and D 
effects. Loci that are closely linked and inherited together, are included in the A effects, 
whereas interactions between loci at distant sites are modeled as part of D effects. 
6.4. Implications of this thesis 
6.4.1. Health implications 
Light smokers often do not consider themselves true smokers, and consequently, they may go 
unidentified by healthcare professionals (Schane, Ling & Glantz 2010). Light smokers are 
rarely advised to quit smoking (Owen et al. 1995, Okuyemi et al. 2001). However, because 
they are often planning to quit (Owen et al. 1995, Zhu et al. 2003, Hyland et al. 2005) and are 
probably less nicotine-dependent than smokers with heavier consumption (Shiffman et al. 
1990), light smokers would be more likely to benefit from cessation interventions. Cessation 
pharmacotherapy has not been studied in light smokers, and current guidelines do not support 
use of medication if the amount smoked is <10 CPD (Winell et al. 2007, Schane, Ling & 
Glantz 2010). However, information, motivation, and support, all of which increase the 
likelihood of quitting, should also be offered to light smokers (Winell et al. 2007, Grief 2011). 
In addition to light and occasional smokers, healthcare professionals should also pay 
attention to subjects who report having reduced their smoking. Possible false beliefs about the 
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diminished health risks should be corrected, and reducers should be advised to quit smoking. 
As studies have shown that smoking reduction predicts cessation (Hughes & Carpenter 2006, 
Broms, Korhonen & Kaprio 2008), quitting interventions might be particularly successful 
among such smokers. Smokers should not be advised to reduce smoking unless the final goal 
is complete abstinence from tobacco (Hughes & Carpenter 2006). 
From the public health point of view, there is a need for better health education about 
the risks of low-rate smoking patterns. Possible reasons for the increase in the proportion of 
low-rate smokers may be false beliefs about a 'safe level of smoking', or intended 'harm 
reduction'. Low-rate smokers may be unaware of the health risks to which they are exposed. 
Information should be targeted to groups in which low-rate smoking patterns are especially 
common: adolescents, students, pregnant women, and certain ethnic minorities (Owen et al. 
1995, Okuyemi et al. 2002, Hyland et al. 2005, Levy, Biener & Rigotti 2009, Pierce, White & 
Messer 2009). Intensive screening of smoking and health education among pregnant women, 
in particular, would be profitable, as women appear to be more prone to the harmful effects of 
smoking than men (Sorheim et al. 2010, Foreman et al. 2011), and smoking during pregnancy 
is a severe health risk for the fetus. As smoke-free policies have had a marked impact on 
tobacco consumption rates (Helakorpi et al. 2004, Helakorpi 2008), greater smoking 
restrictions could result in further benefits. 
Maintenance of good lung function in the elderly is necessary to prevent excess COPD 
morbidity. The previous finding that a large proportion of lung function is determined by 
environmental effects was supported in this study. Environmental factors other than smoking 
were found to have a significant influence on lung function in women aged 63-76 years. 
Disease processes, accidents, sarcopenia (Sharma & Goodwin 2006), occupational or second-
hand smoke exposure (Kerstjens et al. 1997), low physical activity (Amara et al. 2001), and 
malnutrition (McKeever et al. 2008) are among the factors that may predispose to a decline in 
lung function and a concomitant worsening of overall functional capacity and health. Even in 
healthy elderly persons, multiple physiological modifications occur in the lungs over time 
(Chan & Welsh 1998), contributing to the enhanced decline of lung function after the age of 
65 years (Kerstjens et al. 1997). One important factor worsening age-related decline is 
immobilization, which rapidly leads to disability and muscle waste in the elderly. Further, it is 
uncommon for elderly persons to regain the previous functional level (Suetta et al. 2007). 
Thus, physical activity, muscle training, and early and active rehabilitation when needed are 
important. Also, a good nutritional status helps to maintain lung function (McKeever et al. 
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2008). Furthermore, the observed association between mental and respiratory health 
(Goodwin et al. 2007) suggests that avoiding and treating mental problems may prevent 
excessive lung function decline.  
6.4.2. Implications for future research 
This study found that the prevalence of light smoking remained constant at 2.5% among the 
Finnish population between 1975 and 1990. In many other countries, a trend of increasing 
low-rate smoking patterns has been observed. In recent years, the daily number of cigarettes 
among regular smokers has decreased also in Finland; however, the proportion of occasional 
smokers has remained the same for decades. Further research in the current Finnish adult 
population would reveal whether the proportion of light smokers has changed since 1990. 
The risk of COPD increases with pack-years of smoking, which is one reason why the 
disease particularly affects elderly subjects. Constant light smokers are likely to have, on 
average, a slower lung function decline than heavy smokers, and they may therefore develop 
chronic bronchitis and COPD later. In this study, the mean age of light smokers (identified 
from the 1975 study) was 34.5 years in 1981, when the incidence of chronic bronchitis was 
investigated, and 61.5 years at the end of the COPD follow-up. To fully understand the health 
risks associated with light and occasional smoking, lifelong follow-ups of such smokers are 
needed. 
When assessing lung function heritability at two time-points, the genetic factors 
affecting lung function were rather constant, whereas new environmental factors emerged at 
follow-up. Further research is required to recognize such time-specific environmental risk 
factors, as well as to better understand the underlying mechanisms determining lung function. 
As lung function is likely influenced by complex relationships between genetic and 
environmental factors, gene-environment interaction studies are warranted to reveal these 
pathways. 
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7. Conclusions 
This study assessed longitudinally the consistency of light smoking in the Finnish population 
and evaluated which characteristics describe this subgroup of smokers. The risks of chronic 
bronchitis and COPD were estimated according to changes in smoking patterns between 1975 
and 1981, with a particular focus on light smoking and reduced smoking. Further, the 
proportions of genetic and environmental factors affecting lung function were estimated in 
elderly never-smoking Finnish females.  
This study reveals that light smokers form a small, but stable subgroup among Finnish 
adult smokers. However, the finding that most light smokers quit or increase their smoking 
during follow-up indicates considerable turnover on an individual basis. Light smokers are 
more often female, young, well-educated, single, and exhibit a healthier lifestyle than heavy 
smokers. Targeting information about the health risks of low-rate smoking to groups with the 
above-mentioned characteristics seems reasonable. Efforts are required to motivate light 
smokers to quit. As light smoking is increasing globally, and smokers also in Finland 
consume fewer cigarettes than earlier, research on present-day Finnish light smokers is 
warranted. 
The heritability of lung function was found to be lower among elderly never-smoking 
Finnish females than previously reported in other populations. The proportions of genetic and 
environmental factors affecting lung function were assessed longitudinally for the first time. 
Genetic factors influencing FEV1 and FEV1/FVC remained the same, whereas new genes 
emerged to explain part of the observed variance in FVC at follow-up. Environmental factors 
others than smoking were found to be important determinants of lung function in elderly 
females, suggesting that abstinence from tobacco is not enough to maintain good respiratory 
health. Drawing attention to possible external risk factors may help to maintain normal lung 
function in old age. 
This study supports the view that regarding pulmonary disorders no safe level of daily 
smoking exists. The results provide strong evidence that reducing smoking to fewer than five 
cigarettes a day does not protect against chronic bronchitis or COPD. The disease risk 
actually seems to remain unchanged regardless of smoking reduction since moderate smokers 
and increasers exhibited similar risks for regular anticholinergic use. Thus, smoking reduction 
should not be considered an alternative to cessation. Further, this study demonstrated that also 
daily light smoking increases the risk of chronic bronchitis and COPD. The incidence of 
82 
 
chronic bronchitis was screened at an average age of 49 years, and the follow-up for COPD 
ended at an average age of 67 years. Although the prevalence of COPD is highest among the 
oldest age groups, the results show that smoking-induced respiratory disorders often occur 
already in middle-aged individuals. As COPD and chronic bronchitis are likely to cause 
significant disability and morbidity later in life, the possibility of their presence should be 
considered also in light smokers, regardless of age.  
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Appendix 1. Formation of smoking categories describing change in smoking between 1965 and 1981 in Studies 
II and IV. The final categories are presented in the middle column, initial smoking groups on the left, and group 
size on the right. 
 Change in smoking 1975-1981 Smoking categories  N (%) 
Cl
as
sif
ica
tio
n 
in
 S
tu
dy
 II 
Never / occasional → never Constant never smokers 10,083 (46.80) 
Never / occasional / former→ occasional Occasional / non-daily smokers 567 (2.63) 
Former → former Constant former smokers 2,594 (12.04) 
Never → light / moderate / heavy Initiators 354 (1.64) 
Never / occasional / light / moderate / heavy → 
Former  Quitters 1,960 (9.10) 
Former → light / moderate / heavy Recurrent smokers 578 (2.68) 
Light → light Constant light 104 (0.48) 
Moderate → moderate Constant moderate 2,510 (11.65) 
Heavy → heavy Constant heavy 1,048 (4.86) 
Increase in daily light / moderate smoking Increasers 814 (3.78) 
 Decrease in daily moderate / heavy smoking Decreasers 548 (2.54) 
 Misclassifications and illogical reports Others 386 (1.79) 
Cl
as
sif
ica
tio
n 
in
 S
tu
dy
 IV
 
Never → never Never smokers  9,852 (45.7) 
Never / occasional → occasional Occasional smokers  411 (1.91) 
Never → light / moderate,  
occasional → light / moderate / heavy 
Initiators  341 (1.58) 
Former / light / moderate / heavy → former Former smokers  4,130 (19.17) 
Moderate / heavy → moderate Moderate smokers  2,906 (13.49) 
Never / former / light / moderate → heavy Increasers  833 (3.87) 
Moderate → light Moderate → light  176 (0.82) 
Heavy → light Heavy → light  9 (0.04) 
Heavy → heavy Constant heavy smokers  1,053 (4.89) 
Former → light / moderate,  
light → moderate  
Small increase  617 (2.86) 
Light → light Constant light smokers  109 (0.51) 
Misclassifications and illogical reports Others 1,109 (5.15) 
Total   21,546 (100%) 
